Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,3517382,elimination half-life,"After i.v. injection, blood levels decline with an elimination half-life of 3-10 h.",Phenylbutazone in the horse: a review. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3517382/),h,3-10,2380,DB00812,Phenylbutazone
,3517382,Plasma residues,"Plasma residues of the drug at 24 h after a single i.v. dose of 2 g/450 kg average about 0.9 microgram/ml, but considerable variation occurs.",Phenylbutazone in the horse: a review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3517382/),[μg] / [ml],0.9,2381,DB00812,Phenylbutazone
,3517382,residual blood levels,"If dosing is repeated, the plasma residue accumulates to give mean residual blood levels of approximately 4.5 microgram/ml on Day 5 after 4 days of dosing.",Phenylbutazone in the horse: a review. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3517382/),[μg] / [ml],4.5,2382,DB00812,Phenylbutazone
,3517382,time of peak plasma concentration,Access to hay can delay the time of peak plasma concentration to 18 h or longer.,Phenylbutazone in the horse: a review. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3517382/),h,18,2383,DB00812,Phenylbutazone
,3517382,bioavailability,"Under optimal conditions, the bioavailability of oral phenylbutazone is probably in the region of 70%.",Phenylbutazone in the horse: a review. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3517382/),%,70,2384,DB00812,Phenylbutazone
,8116939,volume of distribution at steady-state,"Median volume of distribution at steady-state was 0.274 L/kg (range, 0.190 to 0.401 L/kg).",Pharmacokinetics of phenylbutazone in neonatal foals. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8116939/),[l] / [kg],0.274,10097,DB00812,Phenylbutazone
,8116939,terminal half-life,"Median terminal half-life was 7.4 (6.4 to 22.1) hours, and median total plasma clearance of PBZ for foals in this study was 0.018 L/kg/h (range, 0.013 to 0.038 L/kg/h).",Pharmacokinetics of phenylbutazone in neonatal foals. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8116939/),h,7.4,10098,DB00812,Phenylbutazone
,8116939,total plasma clearance,"Median terminal half-life was 7.4 (6.4 to 22.1) hours, and median total plasma clearance of PBZ for foals in this study was 0.018 L/kg/h (range, 0.013 to 0.038 L/kg/h).",Pharmacokinetics of phenylbutazone in neonatal foals. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8116939/),[l] / [h·kg],0.018,10099,DB00812,Phenylbutazone
,3987792,plasma AUC,"Chronic administration of sulphinpyrazone, in comparison with a single oral dose, led to significant changes in plasma AUC (115.86 to 42.90 mg/l . h), in renal clearance (1.06 to 1.80 l/h), in hepatic intrinsic clearance (319.0 to 598.0 l/h), and in the unbound fraction in plasma 1.15 to 1.69%) and in tissue (2.73 to 1.31%).",Pharmacokinetics of sulphinpyrazone and its major metabolites after a single dose and during chronic treatment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987792/),[mg] / [h·l],115.86 to 42.90,10354,DB00812,Phenylbutazone
,3987792,renal clearance,"Chronic administration of sulphinpyrazone, in comparison with a single oral dose, led to significant changes in plasma AUC (115.86 to 42.90 mg/l . h), in renal clearance (1.06 to 1.80 l/h), in hepatic intrinsic clearance (319.0 to 598.0 l/h), and in the unbound fraction in plasma 1.15 to 1.69%) and in tissue (2.73 to 1.31%).",Pharmacokinetics of sulphinpyrazone and its major metabolites after a single dose and during chronic treatment. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987792/),[l] / [h],1.06 to 1.80,10355,DB00812,Phenylbutazone
,3987792,hepatic intrinsic clearance,"Chronic administration of sulphinpyrazone, in comparison with a single oral dose, led to significant changes in plasma AUC (115.86 to 42.90 mg/l . h), in renal clearance (1.06 to 1.80 l/h), in hepatic intrinsic clearance (319.0 to 598.0 l/h), and in the unbound fraction in plasma 1.15 to 1.69%) and in tissue (2.73 to 1.31%).",Pharmacokinetics of sulphinpyrazone and its major metabolites after a single dose and during chronic treatment. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987792/),[l] / [h],319.0 to 598.0,10356,DB00812,Phenylbutazone
,3987792,volume of distribution,The volume of distribution changed from 20.24 to 52.04 l.,Pharmacokinetics of sulphinpyrazone and its major metabolites after a single dose and during chronic treatment. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987792/),l,20,10357,DB00812,Phenylbutazone
,3987792,volume of distribution,The volume of distribution changed from 20.24 to 52.04 l.,Pharmacokinetics of sulphinpyrazone and its major metabolites after a single dose and during chronic treatment. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987792/),l,52.04,10358,DB00812,Phenylbutazone
,3987792,elimination half-life,Chronic treatment with sulphinpyrazone reduced the plasma AUC of the sulfide and caused a decrease in its elimination half-life (20.9 to 14.3 h).,Pharmacokinetics of sulphinpyrazone and its major metabolites after a single dose and during chronic treatment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987792/),h,20.9 to 14.3,10359,DB00812,Phenylbutazone
,15683768,Cmax,"The measured values (means+/-SD) for Rhodes and Sporobolus hay, respectively, were Cmax 35.59+/-22.36 and 36.55+/-18.99 microg/mL, Tmax 26+/-2.53 and 26.3+/-1.97 h and AUC0-72 h 1552+/-872.6 and 1621+/-903.6 microg h/mL.",Comparison of the effect of Sporobolus virginicus and Rhodes (Chloris gayana) hay diets on the absorption pattern of phenylbutazone in the camel (Camelus dromedarius). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15683768/),[μg] / [ml],35.59,12048,DB00812,Phenylbutazone
,15683768,Cmax,"The measured values (means+/-SD) for Rhodes and Sporobolus hay, respectively, were Cmax 35.59+/-22.36 and 36.55+/-18.99 microg/mL, Tmax 26+/-2.53 and 26.3+/-1.97 h and AUC0-72 h 1552+/-872.6 and 1621+/-903.6 microg h/mL.",Comparison of the effect of Sporobolus virginicus and Rhodes (Chloris gayana) hay diets on the absorption pattern of phenylbutazone in the camel (Camelus dromedarius). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15683768/),[μg] / [ml],36.55,12049,DB00812,Phenylbutazone
,15683768,Tmax,"The measured values (means+/-SD) for Rhodes and Sporobolus hay, respectively, were Cmax 35.59+/-22.36 and 36.55+/-18.99 microg/mL, Tmax 26+/-2.53 and 26.3+/-1.97 h and AUC0-72 h 1552+/-872.6 and 1621+/-903.6 microg h/mL.",Comparison of the effect of Sporobolus virginicus and Rhodes (Chloris gayana) hay diets on the absorption pattern of phenylbutazone in the camel (Camelus dromedarius). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15683768/),h,26,12050,DB00812,Phenylbutazone
,15683768,Tmax,"The measured values (means+/-SD) for Rhodes and Sporobolus hay, respectively, were Cmax 35.59+/-22.36 and 36.55+/-18.99 microg/mL, Tmax 26+/-2.53 and 26.3+/-1.97 h and AUC0-72 h 1552+/-872.6 and 1621+/-903.6 microg h/mL.",Comparison of the effect of Sporobolus virginicus and Rhodes (Chloris gayana) hay diets on the absorption pattern of phenylbutazone in the camel (Camelus dromedarius). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15683768/),h,26.3,12051,DB00812,Phenylbutazone
,15683768,AUC0-72 h,"The measured values (means+/-SD) for Rhodes and Sporobolus hay, respectively, were Cmax 35.59+/-22.36 and 36.55+/-18.99 microg/mL, Tmax 26+/-2.53 and 26.3+/-1.97 h and AUC0-72 h 1552+/-872.6 and 1621+/-903.6 microg h/mL.",Comparison of the effect of Sporobolus virginicus and Rhodes (Chloris gayana) hay diets on the absorption pattern of phenylbutazone in the camel (Camelus dromedarius). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15683768/),[h·μg] / [ml],1552,12052,DB00812,Phenylbutazone
,15683768,AUC0-72 h,"The measured values (means+/-SD) for Rhodes and Sporobolus hay, respectively, were Cmax 35.59+/-22.36 and 36.55+/-18.99 microg/mL, Tmax 26+/-2.53 and 26.3+/-1.97 h and AUC0-72 h 1552+/-872.6 and 1621+/-903.6 microg h/mL.",Comparison of the effect of Sporobolus virginicus and Rhodes (Chloris gayana) hay diets on the absorption pattern of phenylbutazone in the camel (Camelus dromedarius). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15683768/),[h·μg] / [ml],1621,12053,DB00812,Phenylbutazone
over,11499619,half-life,"Although BCP had a long half-life (over 8.5 h), the preliminary pharmacokinetic parameters (0-8 h) were determined: t 1/2, 8.52 +/- 1.96 h; AUC, 419.9 +/- 45.2 microg x h/ml; MRT, 3.29 +/- 0.11 h; CLtot, 5.93 +/- 0.54 ml/h; and Vdss, 19.5 +/- 1.3 l.",Metabolism of bucolome in rats. Stability and biliary excretion of bucolome N-glucuronide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11499619/),h,8.5,13054,DB00812,Phenylbutazone
,11499619,t 1/2,"Although BCP had a long half-life (over 8.5 h), the preliminary pharmacokinetic parameters (0-8 h) were determined: t 1/2, 8.52 +/- 1.96 h; AUC, 419.9 +/- 45.2 microg x h/ml; MRT, 3.29 +/- 0.11 h; CLtot, 5.93 +/- 0.54 ml/h; and Vdss, 19.5 +/- 1.3 l.",Metabolism of bucolome in rats. Stability and biliary excretion of bucolome N-glucuronide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11499619/),h,8.52,13055,DB00812,Phenylbutazone
,11499619,AUC,"Although BCP had a long half-life (over 8.5 h), the preliminary pharmacokinetic parameters (0-8 h) were determined: t 1/2, 8.52 +/- 1.96 h; AUC, 419.9 +/- 45.2 microg x h/ml; MRT, 3.29 +/- 0.11 h; CLtot, 5.93 +/- 0.54 ml/h; and Vdss, 19.5 +/- 1.3 l.",Metabolism of bucolome in rats. Stability and biliary excretion of bucolome N-glucuronide. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11499619/),[h·μg] / [ml],419.9,13056,DB00812,Phenylbutazone
,11499619,MRT,"Although BCP had a long half-life (over 8.5 h), the preliminary pharmacokinetic parameters (0-8 h) were determined: t 1/2, 8.52 +/- 1.96 h; AUC, 419.9 +/- 45.2 microg x h/ml; MRT, 3.29 +/- 0.11 h; CLtot, 5.93 +/- 0.54 ml/h; and Vdss, 19.5 +/- 1.3 l.",Metabolism of bucolome in rats. Stability and biliary excretion of bucolome N-glucuronide. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11499619/),h,3.29,13057,DB00812,Phenylbutazone
,11499619,CLtot,"Although BCP had a long half-life (over 8.5 h), the preliminary pharmacokinetic parameters (0-8 h) were determined: t 1/2, 8.52 +/- 1.96 h; AUC, 419.9 +/- 45.2 microg x h/ml; MRT, 3.29 +/- 0.11 h; CLtot, 5.93 +/- 0.54 ml/h; and Vdss, 19.5 +/- 1.3 l.",Metabolism of bucolome in rats. Stability and biliary excretion of bucolome N-glucuronide. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11499619/),[ml] / [h],5.93,13058,DB00812,Phenylbutazone
,11499619,Vdss,"Although BCP had a long half-life (over 8.5 h), the preliminary pharmacokinetic parameters (0-8 h) were determined: t 1/2, 8.52 +/- 1.96 h; AUC, 419.9 +/- 45.2 microg x h/ml; MRT, 3.29 +/- 0.11 h; CLtot, 5.93 +/- 0.54 ml/h; and Vdss, 19.5 +/- 1.3 l.",Metabolism of bucolome in rats. Stability and biliary excretion of bucolome N-glucuronide. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11499619/),l,19.5,13059,DB00812,Phenylbutazone
,30499176,volume of distribution at steady state,"The volume of distribution at steady state, systemic clearance, and terminal half-life was 0.194 ± 0.019 L/kg, 23.9 ± 4.48 mL/h/kg, and 10.9 ± 5.32 hours, respectively.","Phenylbutazone blood and urine concentrations, pharmacokinetics, and effects on biomarkers of inflammation in horses following intravenous and oral administration of clinical doses. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30499176/),[l] / [kg],0.194,24007,DB00812,Phenylbutazone
,30499176,systemic clearance,"The volume of distribution at steady state, systemic clearance, and terminal half-life was 0.194 ± 0.019 L/kg, 23.9 ± 4.48 mL/h/kg, and 10.9 ± 5.32 hours, respectively.","Phenylbutazone blood and urine concentrations, pharmacokinetics, and effects on biomarkers of inflammation in horses following intravenous and oral administration of clinical doses. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30499176/),[ml] / [h·kg],23.9,24008,DB00812,Phenylbutazone
,30499176,terminal half-life,"The volume of distribution at steady state, systemic clearance, and terminal half-life was 0.194 ± 0.019 L/kg, 23.9 ± 4.48 mL/h/kg, and 10.9 ± 5.32 hours, respectively.","Phenylbutazone blood and urine concentrations, pharmacokinetics, and effects on biomarkers of inflammation in horses following intravenous and oral administration of clinical doses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30499176/),h,10.9,24009,DB00812,Phenylbutazone
,30499176,terminal half-life,The terminal half-life following oral administration was 13.4 ± 3.01 (paste) and 15.1 ± 3.96 hours (tablets).,"Phenylbutazone blood and urine concentrations, pharmacokinetics, and effects on biomarkers of inflammation in horses following intravenous and oral administration of clinical doses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30499176/),h,13.4,24010,DB00812,Phenylbutazone
,30499176,terminal half-life,The terminal half-life following oral administration was 13.4 ± 3.01 (paste) and 15.1 ± 3.96 hours (tablets).,"Phenylbutazone blood and urine concentrations, pharmacokinetics, and effects on biomarkers of inflammation in horses following intravenous and oral administration of clinical doses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30499176/),h,15.1,24011,DB00812,Phenylbutazone
,7263103,bioavailabilities,Two formulations were found to give bioavailabilities of about 50% that of powder.,The physiologic availability of phenylbutazone tablets marketed in India. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7263103/),%,50,29450,DB00812,Phenylbutazone
,3375589,elimination half-life (t1/2 beta),"Following intravenous injection plasma disposition was described by a three compartment open model with mean elimination half-life (t1/2 beta) and clearance (ClB) values of 35.9 hours and 2.77 ml kg-1 h-1, respectively.","Pharmacokinetics, metabolism and excretion of phenylbutazone in cattle following intravenous, intramuscular and oral administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3375589/),h,35.9,29779,DB00812,Phenylbutazone
,3375589,clearance (ClB),"Following intravenous injection plasma disposition was described by a three compartment open model with mean elimination half-life (t1/2 beta) and clearance (ClB) values of 35.9 hours and 2.77 ml kg-1 h-1, respectively.","Pharmacokinetics, metabolism and excretion of phenylbutazone in cattle following intravenous, intramuscular and oral administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3375589/),[ml] / [h·kg],2.77,29780,DB00812,Phenylbutazone
,6970498,detection limit,"As an example, the practical detection limit for naproxen in plasma was about 0.2 microgram ml-1.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),[μg] / [ml],0.2,31759,DB00812,Phenylbutazone
,6970498,Vc,"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),[1] / [kg],0.038,31760,DB00812,Phenylbutazone
,6970498,Vdss,"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),[1] / [kg],0.138,31761,DB00812,Phenylbutazone
,6970498,t 1/2 (beta,"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),h,21.3,31762,DB00812,Phenylbutazone
,6970498,t 1/2 (alpha),"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),h,0.99,31763,DB00812,Phenylbutazone
,6970498,t 1/2 (ka),"Vc was 0.038 1 kg-1, Vdss 0.138 1 kg-1, t 1/2 (beta) 21.3 hrs, t 1/2 (alpha) 0.99 hr and t 1/2 (ka) 0.67 hr.","HPLC-determination of some antiinflammatory, weak analgesic and uricosuric drugs in human blood plasma and its application to pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6970498/),h,0.67,31764,DB00812,Phenylbutazone
,3834064,clearance,Administration of chloramphenicol sodium succinate to mares reduced mean (+/- SD) phenylbutazone clearance from 0.600 +/- 0.222 to 0.339 +/- 0.123 ml/min per kg and increased mean (+/- SD) half life from 244 +/- 59.8 to 371 +/- 80.8 min and mean residence time from 333 +/- 86.2 to 533 +/- 124 min.,Inhibitory effects of intravenous chloramphenicol sodium succinate on the disposition of phenylbutazone in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3834064/),[ml] / [kg·min],0.600,34086,DB00812,Phenylbutazone
,3834064,clearance,Administration of chloramphenicol sodium succinate to mares reduced mean (+/- SD) phenylbutazone clearance from 0.600 +/- 0.222 to 0.339 +/- 0.123 ml/min per kg and increased mean (+/- SD) half life from 244 +/- 59.8 to 371 +/- 80.8 min and mean residence time from 333 +/- 86.2 to 533 +/- 124 min.,Inhibitory effects of intravenous chloramphenicol sodium succinate on the disposition of phenylbutazone in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3834064/),[ml] / [kg·min],0.339,34087,DB00812,Phenylbutazone
,3834064,half life,Administration of chloramphenicol sodium succinate to mares reduced mean (+/- SD) phenylbutazone clearance from 0.600 +/- 0.222 to 0.339 +/- 0.123 ml/min per kg and increased mean (+/- SD) half life from 244 +/- 59.8 to 371 +/- 80.8 min and mean residence time from 333 +/- 86.2 to 533 +/- 124 min.,Inhibitory effects of intravenous chloramphenicol sodium succinate on the disposition of phenylbutazone in horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3834064/),min,244,34088,DB00812,Phenylbutazone
,3834064,half life,Administration of chloramphenicol sodium succinate to mares reduced mean (+/- SD) phenylbutazone clearance from 0.600 +/- 0.222 to 0.339 +/- 0.123 ml/min per kg and increased mean (+/- SD) half life from 244 +/- 59.8 to 371 +/- 80.8 min and mean residence time from 333 +/- 86.2 to 533 +/- 124 min.,Inhibitory effects of intravenous chloramphenicol sodium succinate on the disposition of phenylbutazone in horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3834064/),min,371,34089,DB00812,Phenylbutazone
,3834064,mean residence time,Administration of chloramphenicol sodium succinate to mares reduced mean (+/- SD) phenylbutazone clearance from 0.600 +/- 0.222 to 0.339 +/- 0.123 ml/min per kg and increased mean (+/- SD) half life from 244 +/- 59.8 to 371 +/- 80.8 min and mean residence time from 333 +/- 86.2 to 533 +/- 124 min.,Inhibitory effects of intravenous chloramphenicol sodium succinate on the disposition of phenylbutazone in horses. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3834064/),min,333,34090,DB00812,Phenylbutazone
,3834064,mean residence time,Administration of chloramphenicol sodium succinate to mares reduced mean (+/- SD) phenylbutazone clearance from 0.600 +/- 0.222 to 0.339 +/- 0.123 ml/min per kg and increased mean (+/- SD) half life from 244 +/- 59.8 to 371 +/- 80.8 min and mean residence time from 333 +/- 86.2 to 533 +/- 124 min.,Inhibitory effects of intravenous chloramphenicol sodium succinate on the disposition of phenylbutazone in horses. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3834064/),min,533,34091,DB00812,Phenylbutazone
,3834064,steady-state volume of distribution,"The mean steady-state volume of distribution of phenylbutazone was unchanged, with mean (+/- SD) values of 187 +/- 28.9 ml/kg in control animals and 170 +/- 32.4 ml/kg after chloramphenicol sodium succinate.",Inhibitory effects of intravenous chloramphenicol sodium succinate on the disposition of phenylbutazone in horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3834064/),[ml] / [kg],187,34092,DB00812,Phenylbutazone
,3834064,steady-state volume of distribution,"The mean steady-state volume of distribution of phenylbutazone was unchanged, with mean (+/- SD) values of 187 +/- 28.9 ml/kg in control animals and 170 +/- 32.4 ml/kg after chloramphenicol sodium succinate.",Inhibitory effects of intravenous chloramphenicol sodium succinate on the disposition of phenylbutazone in horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3834064/),[ml] / [kg],170,34093,DB00812,Phenylbutazone
,7214778,Plasma protein binding,Plasma protein binding was only 86% compared with 95 to 96% in normal subjects (smokers and non-smokers).,The effect of malnutrition on the pharmacokinetics of phenylbutazone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7214778/),%,86,34338,DB00812,Phenylbutazone
,7214778,Plasma protein binding,Plasma protein binding was only 86% compared with 95 to 96% in normal subjects (smokers and non-smokers).,The effect of malnutrition on the pharmacokinetics of phenylbutazone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7214778/),%,95,34339,DB00812,Phenylbutazone
,7214778,Plasma protein binding,Plasma protein binding was only 86% compared with 95 to 96% in normal subjects (smokers and non-smokers).,The effect of malnutrition on the pharmacokinetics of phenylbutazone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7214778/),%,96,34340,DB00812,Phenylbutazone
,4002593,fractional absorption,"The fractional absorption of phenylbutazone was similar in young and older ponies, 0.78 and 0.75, respectively.",Pharmacokinetics of phenylbutazone in two age groups of ponies: a preliminary study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4002593/),,0.78,35234,DB00812,Phenylbutazone
,4002593,fractional absorption,"The fractional absorption of phenylbutazone was similar in young and older ponies, 0.78 and 0.75, respectively.",Pharmacokinetics of phenylbutazone in two age groups of ponies: a preliminary study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4002593/),,0.75,35235,DB00812,Phenylbutazone
,4002593,urinary excretion,"The 24 hour urinary excretion of phenylbutazone and its hydroxylated metabolites, oxyphenbutazone and gamma-hydroxyphenylbutazone, accounted for approximately 25 per cent of the administered intravenous dose in both young and older ponies.",Pharmacokinetics of phenylbutazone in two age groups of ponies: a preliminary study. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4002593/),%,25,35236,DB00812,Phenylbutazone
,6470977,bioavailability,"Intravenous administration of sulfinpyrazone demonstrated that the tablets had a high bioavailability (about 90%), and the time to peak plasma concentration of the sulfide and the amount formed were similar to those seen after oral administration.",Role of the gut flora in the reduction of sulfinpyrazone in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6470977/),%,90,47919,DB00812,Phenylbutazone
,6495891,half life time,"While mofebutazone in the plasma is eliminated with a half life time of 1.9 h, the half life time in the synovial fluid amounted to 7.7 h.",[Kinetics of mofebutazone in plasma and synovial fluid]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6495891/),h,1.9,54099,DB00812,Phenylbutazone
,6495891,half life time,"While mofebutazone in the plasma is eliminated with a half life time of 1.9 h, the half life time in the synovial fluid amounted to 7.7 h.",[Kinetics of mofebutazone in plasma and synovial fluid]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6495891/),h,7.7,54100,DB00812,Phenylbutazone
,12081615,volume of distribution at steady state (Vss),"In regards to whole plasma data, the mean volume of distribution at steady state (Vss), was 140 mL/kg body weight, with a mean (+/-SEM) terminal elimination half-life (t1/2) of 34 +/- 9 h.",Pharmacokinetics of phenylbutazone in beef steers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12081615/),[ml] / [body·kg·weight],140,54156,DB00812,Phenylbutazone
,12081615,terminal elimination half-life (t1/2),"In regards to whole plasma data, the mean volume of distribution at steady state (Vss), was 140 mL/kg body weight, with a mean (+/-SEM) terminal elimination half-life (t1/2) of 34 +/- 9 h.",Pharmacokinetics of phenylbutazone in beef steers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12081615/),h,34,54157,DB00812,Phenylbutazone
,12081615,clearance,The mean clearance was 3.2 mL/h/kg body weight.,Pharmacokinetics of phenylbutazone in beef steers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12081615/),[ml] / [h·kg],3.2,54158,DB00812,Phenylbutazone
,12081615,Vss,"The Vss, as determined from the protein-free plasma fraction, was 54093 mL/kg body weight.",Pharmacokinetics of phenylbutazone in beef steers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12081615/),[ml] / [kg],54093,54159,DB00812,Phenylbutazone
,12081615,t1/2,The mean t1/2 of free phenylbutazone was 35 +/- 12 h.,Pharmacokinetics of phenylbutazone in beef steers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12081615/),h,35,54160,DB00812,Phenylbutazone
,2363243,elimination half-lives,"With respect to the long elimination half-lives (mean values 39-94 h), caution is needed in case of repeated doses (accumulation).",Age-dependent pharmacokinetics of phenylbutazone in calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363243/),h,39-94,55556,DB00812,Phenylbutazone
,1491,plasma half-life,This inhibition as evaluated by a kinetic method was accompanied by a two-fold decrease in the plasma half-life of warfarin from 18-4 h in control animals to 9-6 h in phenylbutazone-treated animals.,Phenylbutazone-warfarin interaction in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1491/),h,18-4,56997,DB00812,Phenylbutazone
,1491,plasma half-life,This inhibition as evaluated by a kinetic method was accompanied by a two-fold decrease in the plasma half-life of warfarin from 18-4 h in control animals to 9-6 h in phenylbutazone-treated animals.,Phenylbutazone-warfarin interaction in the dog. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1491/),h,9-6,56998,DB00812,Phenylbutazone
,1491,unbound fraction,The unbound fraction of warfarin in canine plasma ranged from 1-7 to 4-3% indicating individual differences in the extent of the plasma binding of warfarin in the dog.,Phenylbutazone-warfarin interaction in the dog. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1491/),%,1-7,56999,DB00812,Phenylbutazone
,1491,unbound fraction,The unbound fraction of warfarin in canine plasma ranged from 1-7 to 4-3% indicating individual differences in the extent of the plasma binding of warfarin in the dog.,Phenylbutazone-warfarin interaction in the dog. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1491/),%,4-3,57000,DB00812,Phenylbutazone
,613197,time of occurrence of the peak plasma level,"A statistically significant (P is less than 0.001) difference in the rate of absorption of the two products was apparent, since the mean time of occurrence of the peak plasma level of PBZ for the enteric-coated tablets was 9.0 hours compared with 3.9 hours for the sugar-coated formulation.","Bioavailability evaluation of an enteric-coated phenylbutazone formulation, and cross-over comparison with a sugar-coated product. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/613197/),h,9.0,61513,DB00812,Phenylbutazone
,613197,time of occurrence of the peak plasma level,"A statistically significant (P is less than 0.001) difference in the rate of absorption of the two products was apparent, since the mean time of occurrence of the peak plasma level of PBZ for the enteric-coated tablets was 9.0 hours compared with 3.9 hours for the sugar-coated formulation.","Bioavailability evaluation of an enteric-coated phenylbutazone formulation, and cross-over comparison with a sugar-coated product. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/613197/),h,3.9,61514,DB00812,Phenylbutazone
,359213,biological (elimination) half-life,"The biological (elimination) half-life of phenylbutazone in man is long, with a mean of about 70 hours, and exhibits large interindividual and intraindividual variation.",Clinical pharmacokinetics of phenylbutazone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/359213/),h,70,64502,DB00812,Phenylbutazone
,8588103,elimination half-lives,"The elimination half-lives, total body clearances and apparent volumes of distribution were 6.7 hours, 18.4 ml kg-1 hour-1 and 0.18 litre kg-1, for the normal greyhounds, and 6.4 hours, 19.5 ml kg-1 hour-1 and 0.18 litre kg-1, for the febrile greyhounds.",Disposition and urinary excretion of phenylbutazone in normal and febrile greyhounds. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8588103/),h,6.7,64811,DB00812,Phenylbutazone
,8588103,total body clearances,"The elimination half-lives, total body clearances and apparent volumes of distribution were 6.7 hours, 18.4 ml kg-1 hour-1 and 0.18 litre kg-1, for the normal greyhounds, and 6.4 hours, 19.5 ml kg-1 hour-1 and 0.18 litre kg-1, for the febrile greyhounds.",Disposition and urinary excretion of phenylbutazone in normal and febrile greyhounds. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8588103/),[ml] / [h·kg],18.4,64812,DB00812,Phenylbutazone
,8588103,total body clearances,"The elimination half-lives, total body clearances and apparent volumes of distribution were 6.7 hours, 18.4 ml kg-1 hour-1 and 0.18 litre kg-1, for the normal greyhounds, and 6.4 hours, 19.5 ml kg-1 hour-1 and 0.18 litre kg-1, for the febrile greyhounds.",Disposition and urinary excretion of phenylbutazone in normal and febrile greyhounds. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8588103/),h,6.4,64813,DB00812,Phenylbutazone
,8588103,total body clearances,"The elimination half-lives, total body clearances and apparent volumes of distribution were 6.7 hours, 18.4 ml kg-1 hour-1 and 0.18 litre kg-1, for the normal greyhounds, and 6.4 hours, 19.5 ml kg-1 hour-1 and 0.18 litre kg-1, for the febrile greyhounds.",Disposition and urinary excretion of phenylbutazone in normal and febrile greyhounds. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8588103/),[ml] / [h·kg],19.5,64814,DB00812,Phenylbutazone
,8588103,apparent volumes of distribution,"The elimination half-lives, total body clearances and apparent volumes of distribution were 6.7 hours, 18.4 ml kg-1 hour-1 and 0.18 litre kg-1, for the normal greyhounds, and 6.4 hours, 19.5 ml kg-1 hour-1 and 0.18 litre kg-1, for the febrile greyhounds.",Disposition and urinary excretion of phenylbutazone in normal and febrile greyhounds. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8588103/),[l] / [kg],0.18,64815,DB00812,Phenylbutazone
,7297544,peak plasma levels,After 4 days at 8.8 mg/kg in 2 divided doses mean peak plasma levels of phenylbutazone reached 24 micrograms/ml and showed evidence of cumulation.,Pharmacokinetics of phenylbutazone and its metabolites in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297544/),[μg] / [ml],24,67767,DB00812,Phenylbutazone
,7297544,peak plasma concentrations,"After 4 days at 4.4 micrograms/kg, peak plasma concentrations had fallen to 10 micrograms/ml and mean peak levels just failed to reach 4 micrograms/ml 3 days after reducing dosage to 2.2 mg/kg once daily.",Pharmacokinetics of phenylbutazone and its metabolites in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297544/),[μg] / [ml],10,67768,DB00812,Phenylbutazone
,7297544,peak levels,"After 4 days at 4.4 micrograms/kg, peak plasma concentrations had fallen to 10 micrograms/ml and mean peak levels just failed to reach 4 micrograms/ml 3 days after reducing dosage to 2.2 mg/kg once daily.",Pharmacokinetics of phenylbutazone and its metabolites in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7297544/),[μg] / [ml],4,67769,DB00812,Phenylbutazone
,22860573,Maximum plasma concentration,Maximum plasma concentration following a single oral dose of meloxicam was 915.1 ± 116.9 ng/mL and elimination half-life 10.2 ± 3.0 hours.,Pharmacokinetics and safety of single and multiple oral doses of meloxicam in adult horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22860573/),[ng] / [ml],915.1,69061,DB00812,Phenylbutazone
,22860573,elimination half-life,Maximum plasma concentration following a single oral dose of meloxicam was 915.1 ± 116.9 ng/mL and elimination half-life 10.2 ± 3.0 hours.,Pharmacokinetics and safety of single and multiple oral doses of meloxicam in adult horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22860573/),h,10.2,69062,DB00812,Phenylbutazone
,4039147,Cmax,Cmax (means +/- SEM) decreased from 40.6 +/- 2.9 to 36.25 +/- 1.4 micrograms/ml; the mean area under the plasma level time curve was somewhat higher after additional administration of aluminium hydroxide (n. s.).,The influence of aluminium hydroxide on the bioavailability of feprazone. Single dose study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039147/),[μg] / [ml],40.6,70861,DB00812,Phenylbutazone
,4039147,Cmax,Cmax (means +/- SEM) decreased from 40.6 +/- 2.9 to 36.25 +/- 1.4 micrograms/ml; the mean area under the plasma level time curve was somewhat higher after additional administration of aluminium hydroxide (n. s.).,The influence of aluminium hydroxide on the bioavailability of feprazone. Single dose study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4039147/),[μg] / [ml],36.25,70862,DB00812,Phenylbutazone
,18634209,peak serum concentrations,"After administration of 2 mg/kg phenylbutazone, mean serum concentrations peaked in approximately 7.5 hr at 4.3 +/- 2.02 microg/ml and 9.7 hr at 7.1 +/- 2.36 microg/ml for African and Asian elephants, respectively, while 3 mg/kg dosages resulted in peak serum concentrations of 7.2 +/- 4.06 microg/ml in 8.4 hr and 12.1 +/- 3.13 microg/ml in 14 hr.",Pharmacokinetics of orally administered phenylbutazone in African and Asian elephants (Loxodonta africana and Elephas maximus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18634209/),[μg] / [ml],7.2,70944,DB00812,Phenylbutazone
,18634209,peak serum concentrations,"After administration of 2 mg/kg phenylbutazone, mean serum concentrations peaked in approximately 7.5 hr at 4.3 +/- 2.02 microg/ml and 9.7 hr at 7.1 +/- 2.36 microg/ml for African and Asian elephants, respectively, while 3 mg/kg dosages resulted in peak serum concentrations of 7.2 +/- 4.06 microg/ml in 8.4 hr and 12.1 +/- 3.13 microg/ml in 14 hr.",Pharmacokinetics of orally administered phenylbutazone in African and Asian elephants (Loxodonta africana and Elephas maximus). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18634209/),[μg] / [ml],12.1,70945,DB00812,Phenylbutazone
,18634209,half-life,"The harmonic mean half-life was long, ranging between 13 and 15 hr and 39 and 45 hr for African and Asian elephants, respectively.",Pharmacokinetics of orally administered phenylbutazone in African and Asian elephants (Loxodonta africana and Elephas maximus). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18634209/),h,13 and 15,70946,DB00812,Phenylbutazone
,18634209,half-life,"The harmonic mean half-life was long, ranging between 13 and 15 hr and 39 and 45 hr for African and Asian elephants, respectively.",Pharmacokinetics of orally administered phenylbutazone in African and Asian elephants (Loxodonta africana and Elephas maximus). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18634209/),h,39,70947,DB00812,Phenylbutazone
,18634209,half-life,"The harmonic mean half-life was long, ranging between 13 and 15 hr and 39 and 45 hr for African and Asian elephants, respectively.",Pharmacokinetics of orally administered phenylbutazone in African and Asian elephants (Loxodonta africana and Elephas maximus). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18634209/),h,45,70948,DB00812,Phenylbutazone
,18634209,clearance,"Significant differences (P < 0.0001) in pharmacokinetic values occurred between African and Asian elephants for clearance (27.9 and 7.6 ml/hr/kg, respectively), terminal half-life (15.0 and 38.7 hr, respectively), and mean residence time (22.5 and 55.5 hr, respectively) using 2-mg/kg dosages as an example.",Pharmacokinetics of orally administered phenylbutazone in African and Asian elephants (Loxodonta africana and Elephas maximus). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18634209/),[ml] / [h·kg],27.9,70949,DB00812,Phenylbutazone
,18634209,clearance,"Significant differences (P < 0.0001) in pharmacokinetic values occurred between African and Asian elephants for clearance (27.9 and 7.6 ml/hr/kg, respectively), terminal half-life (15.0 and 38.7 hr, respectively), and mean residence time (22.5 and 55.5 hr, respectively) using 2-mg/kg dosages as an example.",Pharmacokinetics of orally administered phenylbutazone in African and Asian elephants (Loxodonta africana and Elephas maximus). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18634209/),[ml] / [h·kg],7.6,70950,DB00812,Phenylbutazone
,18634209,terminal half-life,"Significant differences (P < 0.0001) in pharmacokinetic values occurred between African and Asian elephants for clearance (27.9 and 7.6 ml/hr/kg, respectively), terminal half-life (15.0 and 38.7 hr, respectively), and mean residence time (22.5 and 55.5 hr, respectively) using 2-mg/kg dosages as an example.",Pharmacokinetics of orally administered phenylbutazone in African and Asian elephants (Loxodonta africana and Elephas maximus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18634209/),h,15.0,70951,DB00812,Phenylbutazone
,18634209,terminal half-life,"Significant differences (P < 0.0001) in pharmacokinetic values occurred between African and Asian elephants for clearance (27.9 and 7.6 ml/hr/kg, respectively), terminal half-life (15.0 and 38.7 hr, respectively), and mean residence time (22.5 and 55.5 hr, respectively) using 2-mg/kg dosages as an example.",Pharmacokinetics of orally administered phenylbutazone in African and Asian elephants (Loxodonta africana and Elephas maximus). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18634209/),h,38.7,70952,DB00812,Phenylbutazone
,18634209,mean residence time,"Significant differences (P < 0.0001) in pharmacokinetic values occurred between African and Asian elephants for clearance (27.9 and 7.6 ml/hr/kg, respectively), terminal half-life (15.0 and 38.7 hr, respectively), and mean residence time (22.5 and 55.5 hr, respectively) using 2-mg/kg dosages as an example.",Pharmacokinetics of orally administered phenylbutazone in African and Asian elephants (Loxodonta africana and Elephas maximus). ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18634209/),h,22.5,70953,DB00812,Phenylbutazone
,18634209,mean residence time,"Significant differences (P < 0.0001) in pharmacokinetic values occurred between African and Asian elephants for clearance (27.9 and 7.6 ml/hr/kg, respectively), terminal half-life (15.0 and 38.7 hr, respectively), and mean residence time (22.5 and 55.5 hr, respectively) using 2-mg/kg dosages as an example.",Pharmacokinetics of orally administered phenylbutazone in African and Asian elephants (Loxodonta africana and Elephas maximus). ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18634209/),h,55.5,70954,DB00812,Phenylbutazone
,7463328,elimination half-life,"The mean elimination half-life was 77 hr (54-99 hr), and there was a linear relationship between the dose and the area under the plasma concentration curve.",Pharmacokinetics of phenylbutazone in healthy subjects after oral administration of single and multiple doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7463328/),h,77,73112,DB00812,Phenylbutazone
,1595963,volume of distribution at steady state,Significant (P less than or equal to 0.05) increase was evident in the 12-hour mean concentration of phenylbutazone (11.45 +/- 1.66 micrograms/ml without probenecid; 14.56 +/- 1.20 micrograms/ml with probenecid) along with significant (P less than or equal to 0.05) reduction in its volume of distribution at steady state associated with concurrent probenecid administration (218.6 +/- 11.52 ml/kg without probenecid; 169.4 +/- 9.25 ml/kg with probenecid).,Effect of probenecid on the pharmacokinetics of flunixin meglumine and phenylbutazone in healthy mares. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1595963/),[ml] / [kg],218.6,74500,DB00812,Phenylbutazone
,1595963,volume of distribution at steady state,Significant (P less than or equal to 0.05) increase was evident in the 12-hour mean concentration of phenylbutazone (11.45 +/- 1.66 micrograms/ml without probenecid; 14.56 +/- 1.20 micrograms/ml with probenecid) along with significant (P less than or equal to 0.05) reduction in its volume of distribution at steady state associated with concurrent probenecid administration (218.6 +/- 11.52 ml/kg without probenecid; 169.4 +/- 9.25 ml/kg with probenecid).,Effect of probenecid on the pharmacokinetics of flunixin meglumine and phenylbutazone in healthy mares. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1595963/),[ml] / [kg],169.4,74501,DB00812,Phenylbutazone
,2316911,biologic half-life,The harmonic mean of the biologic half-life of PBZ was 62.6 +/- 12.9 hours after oral administration and 61.6 +/- 7.2 hours after IV administration.,Pharmacokinetics of phenylbutazone given intravenously or orally in mature Holstein bulls. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316911/),h,62.6,75220,DB00812,Phenylbutazone
,2316911,biologic half-life,The harmonic mean of the biologic half-life of PBZ was 62.6 +/- 12.9 hours after oral administration and 61.6 +/- 7.2 hours after IV administration.,Pharmacokinetics of phenylbutazone given intravenously or orally in mature Holstein bulls. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316911/),h,61.6,75221,DB00812,Phenylbutazone
,2316911,mean residence time,"The mean residence time was 94.61 +/- 8.44 hours and 90.49 +/- 8.93 hours for oral and IV administration, respectively.",Pharmacokinetics of phenylbutazone given intravenously or orally in mature Holstein bulls. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316911/),h,94.61,75222,DB00812,Phenylbutazone
,2316911,mean residence time,"The mean residence time was 94.61 +/- 8.44 hours and 90.49 +/- 8.93 hours for oral and IV administration, respectively.",Pharmacokinetics of phenylbutazone given intravenously or orally in mature Holstein bulls. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316911/),h,90.49,75223,DB00812,Phenylbutazone
,2316911,total body clearance,"The mean total body clearance was 0.0015 +/- 0.0003 L/h/kg, with the mean apparent volume of distribution 0.134 +/- 0.021 L/kg.",Pharmacokinetics of phenylbutazone given intravenously or orally in mature Holstein bulls. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316911/),[l] / [h·kg],0.0015,75224,DB00812,Phenylbutazone
,2316911,apparent volume of distribution,"The mean total body clearance was 0.0015 +/- 0.0003 L/h/kg, with the mean apparent volume of distribution 0.134 +/- 0.021 L/kg.",Pharmacokinetics of phenylbutazone given intravenously or orally in mature Holstein bulls. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316911/),[l] / [kg],0.134,75225,DB00812,Phenylbutazone
,2316911,bioavailability,Mean bioavailability was 73 +/- 2% after oral administration.,Pharmacokinetics of phenylbutazone given intravenously or orally in mature Holstein bulls. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316911/),%,73,75226,DB00812,Phenylbutazone
,1788989,elimination half-life,"2. The mean elimination half-life of feprazone after a single oral dose in the healthy volunteers was 22.3 h, the mean apparent clearance 0.0051 1/h per kg and the mean volume of distribution 0.1681/kg.",The pharmacokinetics of single oral doses of feprazone in healthy volunteers and elderly patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1788989/),h,22.3,75695,DB00812,Phenylbutazone
,1788989,apparent clearance,"2. The mean elimination half-life of feprazone after a single oral dose in the healthy volunteers was 22.3 h, the mean apparent clearance 0.0051 1/h per kg and the mean volume of distribution 0.1681/kg.",The pharmacokinetics of single oral doses of feprazone in healthy volunteers and elderly patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1788989/),[1] / [h·kg],0.0051,75696,DB00812,Phenylbutazone
,1788989,volume of distribution,"2. The mean elimination half-life of feprazone after a single oral dose in the healthy volunteers was 22.3 h, the mean apparent clearance 0.0051 1/h per kg and the mean volume of distribution 0.1681/kg.",The pharmacokinetics of single oral doses of feprazone in healthy volunteers and elderly patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1788989/),1/[kg],0.1681,75697,DB00812,Phenylbutazone
,786687,elimination half-life,"The elimination half-life in the two subjects, calculated from the decline between 3 and 8 hours, was 2.7 and 2.2 hours.",Biotransformation and pharmacokinetics of sulfinpyrazone (Anturan) in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/786687/),h,2.7,78205,DB00812,Phenylbutazone
,786687,elimination half-life,"The elimination half-life in the two subjects, calculated from the decline between 3 and 8 hours, was 2.7 and 2.2 hours.",Biotransformation and pharmacokinetics of sulfinpyrazone (Anturan) in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/786687/),h,2.2,78206,DB00812,Phenylbutazone
,16612034,absolute bioavailability,"The corresponding absolute bioavailability of PBZ was 100 +/- 32%, 96 +/- 19%, and 100 +/- 17%, and the maximal PBZ concentrations were 42 +/- 3.4, 74 +/- 8.8, and 119 +/- 18.2 microg/mL.",Simultaneous and minimally invasive assessment of muscle tolerance and bioavailability of different volumes of an intramuscular formulation in the same animals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16612034/),%,100,79274,DB00812,Phenylbutazone
,16612034,absolute bioavailability,"The corresponding absolute bioavailability of PBZ was 100 +/- 32%, 96 +/- 19%, and 100 +/- 17%, and the maximal PBZ concentrations were 42 +/- 3.4, 74 +/- 8.8, and 119 +/- 18.2 microg/mL.",Simultaneous and minimally invasive assessment of muscle tolerance and bioavailability of different volumes of an intramuscular formulation in the same animals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16612034/),%,96,79275,DB00812,Phenylbutazone
,16612034,absolute bioavailability,"The corresponding absolute bioavailability of PBZ was 100 +/- 32%, 96 +/- 19%, and 100 +/- 17%, and the maximal PBZ concentrations were 42 +/- 3.4, 74 +/- 8.8, and 119 +/- 18.2 microg/mL.",Simultaneous and minimally invasive assessment of muscle tolerance and bioavailability of different volumes of an intramuscular formulation in the same animals. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16612034/),%,100,79276,DB00812,Phenylbutazone
,16612034,maximal PBZ concentrations,"The corresponding absolute bioavailability of PBZ was 100 +/- 32%, 96 +/- 19%, and 100 +/- 17%, and the maximal PBZ concentrations were 42 +/- 3.4, 74 +/- 8.8, and 119 +/- 18.2 microg/mL.",Simultaneous and minimally invasive assessment of muscle tolerance and bioavailability of different volumes of an intramuscular formulation in the same animals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16612034/),[μg] / [ml],42,79277,DB00812,Phenylbutazone
,16612034,maximal PBZ concentrations,"The corresponding absolute bioavailability of PBZ was 100 +/- 32%, 96 +/- 19%, and 100 +/- 17%, and the maximal PBZ concentrations were 42 +/- 3.4, 74 +/- 8.8, and 119 +/- 18.2 microg/mL.",Simultaneous and minimally invasive assessment of muscle tolerance and bioavailability of different volumes of an intramuscular formulation in the same animals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16612034/),[μg] / [ml],74,79278,DB00812,Phenylbutazone
,16612034,maximal PBZ concentrations,"The corresponding absolute bioavailability of PBZ was 100 +/- 32%, 96 +/- 19%, and 100 +/- 17%, and the maximal PBZ concentrations were 42 +/- 3.4, 74 +/- 8.8, and 119 +/- 18.2 microg/mL.",Simultaneous and minimally invasive assessment of muscle tolerance and bioavailability of different volumes of an intramuscular formulation in the same animals. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16612034/),[μg] / [ml],119,79279,DB00812,Phenylbutazone
,16612034,plasma clearance,The plasma clearance of PBZ (i.v.) was 4.2 +/- 0.94 mL.kg(-1).,Simultaneous and minimally invasive assessment of muscle tolerance and bioavailability of different volumes of an intramuscular formulation in the same animals. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16612034/),[ml] / [kg],4.2,79280,DB00812,Phenylbutazone
,8110026,elimination half-life,"The first one, phenylbutazone, is characterized by a fairly short elimination half-life (3-6 hours) in dogs, whereas the other one, naproxen, has an average half-life of 67 hours in this species.",Plasma and tissue kinetics of phenylbutazone and naproxen in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8110026/),h,3-6,86812,DB00812,Phenylbutazone
,8110026,half-life,"The first one, phenylbutazone, is characterized by a fairly short elimination half-life (3-6 hours) in dogs, whereas the other one, naproxen, has an average half-life of 67 hours in this species.",Plasma and tissue kinetics of phenylbutazone and naproxen in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8110026/),h,67,86813,DB00812,Phenylbutazone
,8110026,Plasma peak concentrations,Plasma peak concentrations of 49-75 micrograms/ml were reached.,Plasma and tissue kinetics of phenylbutazone and naproxen in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8110026/),[μg] / [ml],49-75,86814,DB00812,Phenylbutazone
,8110026,half-life,"Due to a considerably longer half-life in the exudate than in plasma (7.3-18 hours), the concentration in the exudate exceeded that in plasma at about 20 hours.",Plasma and tissue kinetics of phenylbutazone and naproxen in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8110026/),h,7.3-18,86815,DB00812,Phenylbutazone
,9123796,elimination half-lives (t1/2 beta),"Phenylbutazone was eliminated slowly with mean (se) elimination half-lives (t1/2 beta) of 15.3 (1.15) hours and 22.0 (3.32) hours after intravenous and oral administration, respectively.",Pharmacokinetic and pharmacodynamic studies on phenylbutazone and oxyphenbutazone in goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9123796/),h,15.3,86816,DB00812,Phenylbutazone
,9123796,elimination half-lives (t1/2 beta),"Phenylbutazone was eliminated slowly with mean (se) elimination half-lives (t1/2 beta) of 15.3 (1.15) hours and 22.0 (3.32) hours after intravenous and oral administration, respectively.",Pharmacokinetic and pharmacodynamic studies on phenylbutazone and oxyphenbutazone in goats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9123796/),h,22.0,86817,DB00812,Phenylbutazone
,9123796,bioavailability,"The bioavailability of phenylbutazone paste administered orally was 61 (7) per cent (corrected by the t1/2 beta) and relatively slow absorption was observed, as indicated by a time of maximum drug concentration (tmax) of 3.47 (0.39) hours and a mean absorption time (MAT) of 10.4 (8.61) hours.",Pharmacokinetic and pharmacodynamic studies on phenylbutazone and oxyphenbutazone in goats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9123796/),%,61,86818,DB00812,Phenylbutazone
,9123796,time of maximum drug concentration (tmax),"The bioavailability of phenylbutazone paste administered orally was 61 (7) per cent (corrected by the t1/2 beta) and relatively slow absorption was observed, as indicated by a time of maximum drug concentration (tmax) of 3.47 (0.39) hours and a mean absorption time (MAT) of 10.4 (8.61) hours.",Pharmacokinetic and pharmacodynamic studies on phenylbutazone and oxyphenbutazone in goats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9123796/),h,3.47,86819,DB00812,Phenylbutazone
,9123796,mean absorption time (MAT),"The bioavailability of phenylbutazone paste administered orally was 61 (7) per cent (corrected by the t1/2 beta) and relatively slow absorption was observed, as indicated by a time of maximum drug concentration (tmax) of 3.47 (0.39) hours and a mean absorption time (MAT) of 10.4 (8.61) hours.",Pharmacokinetic and pharmacodynamic studies on phenylbutazone and oxyphenbutazone in goats. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9123796/),h,10.4,86820,DB00812,Phenylbutazone
,8259696,relative bioavailabilities,"5. In comparison with a gavage study in the same rat (strain and age), bioavailability was lower in the diet study with relative bioavailabilities of 27, 22 and 61% for paracetamol, antipyrine and phenylbutazone, respectively.",Assessment of drug exposure in rat dietary studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8259696/),%,27,89177,DB00812,Phenylbutazone
,8259696,relative bioavailabilities,"5. In comparison with a gavage study in the same rat (strain and age), bioavailability was lower in the diet study with relative bioavailabilities of 27, 22 and 61% for paracetamol, antipyrine and phenylbutazone, respectively.",Assessment of drug exposure in rat dietary studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8259696/),%,22,89178,DB00812,Phenylbutazone
,8259696,relative bioavailabilities,"5. In comparison with a gavage study in the same rat (strain and age), bioavailability was lower in the diet study with relative bioavailabilities of 27, 22 and 61% for paracetamol, antipyrine and phenylbutazone, respectively.",Assessment of drug exposure in rat dietary studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8259696/),%,61,89179,DB00812,Phenylbutazone
,8259696,elimination half-lives,"6. In conclusion, drug exposure as expressed by AUC24 and Cmax can be accurately determined in rat studies using compound administration in the diet by measuring concentrations at three selected time points for compounds with elimination half-lives ranging from about 1 to 5 h.",Assessment of drug exposure in rat dietary studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8259696/),h,1 to 5,89180,DB00812,Phenylbutazone
,9350255,plasma clearance (Cl),The median (range) plasma clearance (Cl) was 8.20 (4.96-10.2) mL/min.,Pharmacokinetics of intravenous and intragastric cimetidine in horses. I. Effects of intravenous cimetidine on pharmacokinetics of intravenous phenylbutazone. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350255/),[ml] / [min],8.20,92144,DB00812,Phenylbutazone
,9350255,steady-state volume of distribution (Vdss),"kg of body weight, that of the steady-state volume of distribution (Vdss) was 0.771 (0.521-1.15) L/kg bw, and that of the terminal elimination half-life (t1/2 beta) was 92.4 (70.6-125) minutes.",Pharmacokinetics of intravenous and intragastric cimetidine in horses. I. Effects of intravenous cimetidine on pharmacokinetics of intravenous phenylbutazone. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350255/),[l] / [bw·kg],0.771,92145,DB00812,Phenylbutazone
,9350255,terminal elimination half-life (t1/2 beta),"kg of body weight, that of the steady-state volume of distribution (Vdss) was 0.771 (0.521-1.15) L/kg bw, and that of the terminal elimination half-life (t1/2 beta) was 92.4 (70.6-125) minutes.",Pharmacokinetics of intravenous and intragastric cimetidine in horses. I. Effects of intravenous cimetidine on pharmacokinetics of intravenous phenylbutazone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350255/),min,92.4,92146,DB00812,Phenylbutazone
,9350255,renal clearance,The median (range) renal clearance of cimetidine was 4.08 (2.19-6.23) mL/min.kg bw or 55.4 (36.3-81.8)% of the corresponding plasma clearance.,Pharmacokinetics of intravenous and intragastric cimetidine in horses. I. Effects of intravenous cimetidine on pharmacokinetics of intravenous phenylbutazone. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350255/),[ml] / [bw·kg·min],4.08,92147,DB00812,Phenylbutazone
,9350255,renal clearance,The median (range) renal clearance of cimetidine was 4.08 (2.19-6.23) mL/min.kg bw or 55.4 (36.3-81.8)% of the corresponding plasma clearance.,Pharmacokinetics of intravenous and intragastric cimetidine in horses. I. Effects of intravenous cimetidine on pharmacokinetics of intravenous phenylbutazone. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350255/),,55.,92148,DB00812,Phenylbutazone
,9350255,bioavailability,The median (range) extent of intragastric bioavailability was 14.4 (6.82-21.8)% and the maximum plasma concentration after intragastric administration was 0.31 (0.24-0.50) microgram/mL.,Pharmacokinetics of intravenous and intragastric cimetidine in horses. I. Effects of intravenous cimetidine on pharmacokinetics of intravenous phenylbutazone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350255/),%,14.4,92149,DB00812,Phenylbutazone
,9350255,maximum plasma concentration,The median (range) extent of intragastric bioavailability was 14.4 (6.82-21.8)% and the maximum plasma concentration after intragastric administration was 0.31 (0.24-0.50) microgram/mL.,Pharmacokinetics of intravenous and intragastric cimetidine in horses. I. Effects of intravenous cimetidine on pharmacokinetics of intravenous phenylbutazone. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9350255/),[μg] / [ml],0.31,92150,DB00812,Phenylbutazone
,2906600,plasma clearance,(S)-Acenocoumarol plasma clearance was enhanced (2.8 +/- 0.15 vs. 1.54 +/- 0.14 ml/min) but the unbound plasma clearance was reduced by 50% (67 +/- 9 vs. 140 +/- 27 ml/min).,"Phenylbutazone-hydroxycoumarol interactions. Effects on steady state disposition, hepatocellular distribution, and biliary excretion of (S)-acenocoumarol in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906600/),[ml] / [min],2.8,92466,DB00812,Phenylbutazone
,2906600,plasma clearance,(S)-Acenocoumarol plasma clearance was enhanced (2.8 +/- 0.15 vs. 1.54 +/- 0.14 ml/min) but the unbound plasma clearance was reduced by 50% (67 +/- 9 vs. 140 +/- 27 ml/min).,"Phenylbutazone-hydroxycoumarol interactions. Effects on steady state disposition, hepatocellular distribution, and biliary excretion of (S)-acenocoumarol in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906600/),[ml] / [min],1.54,92467,DB00812,Phenylbutazone
,2906600,unbound plasma clearance,(S)-Acenocoumarol plasma clearance was enhanced (2.8 +/- 0.15 vs. 1.54 +/- 0.14 ml/min) but the unbound plasma clearance was reduced by 50% (67 +/- 9 vs. 140 +/- 27 ml/min).,"Phenylbutazone-hydroxycoumarol interactions. Effects on steady state disposition, hepatocellular distribution, and biliary excretion of (S)-acenocoumarol in rats. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906600/),[ml] / [min],67,92468,DB00812,Phenylbutazone
,2906600,unbound plasma clearance,(S)-Acenocoumarol plasma clearance was enhanced (2.8 +/- 0.15 vs. 1.54 +/- 0.14 ml/min) but the unbound plasma clearance was reduced by 50% (67 +/- 9 vs. 140 +/- 27 ml/min).,"Phenylbutazone-hydroxycoumarol interactions. Effects on steady state disposition, hepatocellular distribution, and biliary excretion of (S)-acenocoumarol in rats. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906600/),[ml] / [min],140,92469,DB00812,Phenylbutazone
,2906600,biliary excretion,"The biliary excretion of free metabolites, however, was greatly increased (62 +/- 7 vs. 22 +/- 6 ng/min for 6-hydroxy-acenocoumarol; 337 +/- 38 vs. 141 +/- 32 ng/min for 7-hydroxy-acenocoumarol).","Phenylbutazone-hydroxycoumarol interactions. Effects on steady state disposition, hepatocellular distribution, and biliary excretion of (S)-acenocoumarol in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906600/),[ng] / [min],62,92470,DB00812,Phenylbutazone
,2906600,biliary excretion,"The biliary excretion of free metabolites, however, was greatly increased (62 +/- 7 vs. 22 +/- 6 ng/min for 6-hydroxy-acenocoumarol; 337 +/- 38 vs. 141 +/- 32 ng/min for 7-hydroxy-acenocoumarol).","Phenylbutazone-hydroxycoumarol interactions. Effects on steady state disposition, hepatocellular distribution, and biliary excretion of (S)-acenocoumarol in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906600/),[ng] / [min],22,92471,DB00812,Phenylbutazone
,2906600,biliary excretion,"The biliary excretion of free metabolites, however, was greatly increased (62 +/- 7 vs. 22 +/- 6 ng/min for 6-hydroxy-acenocoumarol; 337 +/- 38 vs. 141 +/- 32 ng/min for 7-hydroxy-acenocoumarol).","Phenylbutazone-hydroxycoumarol interactions. Effects on steady state disposition, hepatocellular distribution, and biliary excretion of (S)-acenocoumarol in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906600/),[ng] / [min],337,92472,DB00812,Phenylbutazone
,2906600,biliary excretion,"The biliary excretion of free metabolites, however, was greatly increased (62 +/- 7 vs. 22 +/- 6 ng/min for 6-hydroxy-acenocoumarol; 337 +/- 38 vs. 141 +/- 32 ng/min for 7-hydroxy-acenocoumarol).","Phenylbutazone-hydroxycoumarol interactions. Effects on steady state disposition, hepatocellular distribution, and biliary excretion of (S)-acenocoumarol in rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906600/),[ng] / [min],141,92473,DB00812,Phenylbutazone
,2906600,rate constant,This effect is probably due to stimulation of a hepatic biliary transport system; the rate constant for transport of 7-hydroxy-acenocoumarol was enhanced 5-fold (0.107 +/- 0.03 vs. 0.021 +/- 0.007 min-1).,"Phenylbutazone-hydroxycoumarol interactions. Effects on steady state disposition, hepatocellular distribution, and biliary excretion of (S)-acenocoumarol in rats. ",Km-Q52,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906600/),1/[min],0.107,92474,DB00812,Phenylbutazone
,2906600,rate constant,This effect is probably due to stimulation of a hepatic biliary transport system; the rate constant for transport of 7-hydroxy-acenocoumarol was enhanced 5-fold (0.107 +/- 0.03 vs. 0.021 +/- 0.007 min-1).,"Phenylbutazone-hydroxycoumarol interactions. Effects on steady state disposition, hepatocellular distribution, and biliary excretion of (S)-acenocoumarol in rats. ",Km-Q52,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2906600/),1/[min],0.021,92475,DB00812,Phenylbutazone
,6840173,plasma half-lives,"The plasma half-lives of sulfinpyrazone, the sulfone and the sulfide were 3.7, 3.2 and 14.7 h, respectively, during steady-state.",Plasma levels of sulfinpyrazone and of two of its metabolites after a single dose and during the steady state. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840173/),h,3.7,93348,DB00812,Phenylbutazone
,6840173,plasma half-lives,"The plasma half-lives of sulfinpyrazone, the sulfone and the sulfide were 3.7, 3.2 and 14.7 h, respectively, during steady-state.",Plasma levels of sulfinpyrazone and of two of its metabolites after a single dose and during the steady state. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840173/),h,3.2,93349,DB00812,Phenylbutazone
,6840173,plasma half-lives,"The plasma half-lives of sulfinpyrazone, the sulfone and the sulfide were 3.7, 3.2 and 14.7 h, respectively, during steady-state.",Plasma levels of sulfinpyrazone and of two of its metabolites after a single dose and during the steady state. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6840173/),h,14.7,93350,DB00812,Phenylbutazone
,4050150,half life time,The half life time of mofebutazone of 1.9 h is considerably shorter than that of phenylbutazone (54-99 h).,"[Pharmacology, toxicology and pharmacokinetics of mofebutazone]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4050150/),h,1.9,100436,DB00812,Phenylbutazone
,4050150,half life time,The half life time of mofebutazone of 1.9 h is considerably shorter than that of phenylbutazone (54-99 h).,"[Pharmacology, toxicology and pharmacokinetics of mofebutazone]. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4050150/),h,54-99,100437,DB00812,Phenylbutazone
,4050150,plasma protein binding quota,"In spite of a high plasma protein binding quota of 99%, mofebutazone is classed among those substances with a medium binding potential.","[Pharmacology, toxicology and pharmacokinetics of mofebutazone]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4050150/),%,99,100438,DB00812,Phenylbutazone
,3604253,bioavailability,"Phenylbutazone was rapidly and extensively absorbed after oral administration, and its bioavailability was 91% assessed by comparison of plasma AUCs of unchanged drug after p.o. and i.v. administration.",The bioavailability of phenylbutazone in the horse. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3604253/),%,91,100489,DB00812,Phenylbutazone
,3604253,plasma elimination half-life,The plasma elimination half-life of phenylbutazone was 9.7 h and this was independent of the route of administration.,The bioavailability of phenylbutazone in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3604253/),h,9.7,100490,DB00812,Phenylbutazone
,10505957,maximum plasma concentrations,"Average maximum plasma concentrations of PBZ (16.43 microg/ml) and OPBZ (2.37 microg/ml) were attained at 0.76 and 7.17 h, respectively.",Disposition and tolerance of suxibuzone in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10505957/),[μg] / [ml],16.43,100983,DB00812,Phenylbutazone
,10505957,maximum plasma concentrations,"Average maximum plasma concentrations of PBZ (16.43 microg/ml) and OPBZ (2.37 microg/ml) were attained at 0.76 and 7.17 h, respectively.",Disposition and tolerance of suxibuzone in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10505957/),[μg] / [ml],2.37,100984,DB00812,Phenylbutazone
,10505957,mean residence time (MRT),The mean residence time (MRT) of PBZ was 6.96 h in plasma.,Disposition and tolerance of suxibuzone in horses. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10505957/),h,6.96,100985,DB00812,Phenylbutazone
,10505957,MRT,"Oxyphenbutazone plasma concentrations were below those reached by phenylbutazone during the first 12 h after suxibuzone administration, even though its values were detectable for at least 24 h (MRT = 10.65 h).",Disposition and tolerance of suxibuzone in horses. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10505957/),h,10.65,100986,DB00812,Phenylbutazone
,10505957,Synovial fluid concentrations,Synovial fluid concentrations of PBZ and OPBZ were 2.87+/-0.37 microg/ml and 0.97+/-0.08 microg/ml at 9 h after suxibuzone administration and exceeded IC50 of PGE2 for at least this time.,Disposition and tolerance of suxibuzone in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10505957/),[μg] / [ml],2.87,100987,DB00812,Phenylbutazone
,10505957,Synovial fluid concentrations,Synovial fluid concentrations of PBZ and OPBZ were 2.87+/-0.37 microg/ml and 0.97+/-0.08 microg/ml at 9 h after suxibuzone administration and exceeded IC50 of PGE2 for at least this time.,Disposition and tolerance of suxibuzone in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10505957/),[μg] / [ml],0.97,100988,DB00812,Phenylbutazone
,7587949,Ki's,"Kinetic studies conducted on sulfinpyrazone and two major metabolites, sulfinpyrazone sulfide and sulfinpyrazone sulfone, in microsomes prepared from three human livers give mean Ki's of 230 microM, 17 microM, and 73 microM respectively.",Inhibition of (S)-warfarin metabolism by sulfinpyrazone and its metabolites. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587949/),μM,230,102161,DB00812,Phenylbutazone
,7587949,Ki's,"Kinetic studies conducted on sulfinpyrazone and two major metabolites, sulfinpyrazone sulfide and sulfinpyrazone sulfone, in microsomes prepared from three human livers give mean Ki's of 230 microM, 17 microM, and 73 microM respectively.",Inhibition of (S)-warfarin metabolism by sulfinpyrazone and its metabolites. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587949/),μM,17,102162,DB00812,Phenylbutazone
,7587949,Ki's,"Kinetic studies conducted on sulfinpyrazone and two major metabolites, sulfinpyrazone sulfide and sulfinpyrazone sulfone, in microsomes prepared from three human livers give mean Ki's of 230 microM, 17 microM, and 73 microM respectively.",Inhibition of (S)-warfarin metabolism by sulfinpyrazone and its metabolites. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7587949/),μM,73,102163,DB00812,Phenylbutazone
,782467,AUC,"The corresponding AUC of three specifically determined metabolites, i.e. oxyphenbutazone, gamma-hydroxyphenylbutazone and p,gamma-dihydroxyphenylbutazone were 23%, 2% and 0.5%, respectively.",Metabolism of phenylbutazone in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/782467/),%,23,103968,DB00812,Phenylbutazone
,782467,AUC,"The corresponding AUC of three specifically determined metabolites, i.e. oxyphenbutazone, gamma-hydroxyphenylbutazone and p,gamma-dihydroxyphenylbutazone were 23%, 2% and 0.5%, respectively.",Metabolism of phenylbutazone in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/782467/),%,2,103969,DB00812,Phenylbutazone
,782467,AUC,"The corresponding AUC of three specifically determined metabolites, i.e. oxyphenbutazone, gamma-hydroxyphenylbutazone and p,gamma-dihydroxyphenylbutazone were 23%, 2% and 0.5%, respectively.",Metabolism of phenylbutazone in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/782467/),%,0.5,103970,DB00812,Phenylbutazone
,7059415,half-life,Sulphinpyrazone was rapidly absorbed and eliminated with a half-life of approximately 4 h irrespective of dose.,Pharmacokinetics of single doses of sulphinpyrazone and its major metabolites in plasma and urine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059415/),h,4,122453,DB00812,Phenylbutazone
,7059415,half-life,3 Plasma concentrations of the sulphone were low and peaked before those of the sulphide; its mean half-life was 3.1 h.,Pharmacokinetics of single doses of sulphinpyrazone and its major metabolites in plasma and urine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059415/),h,3.1,122454,DB00812,Phenylbutazone
,7059415,half-life,"The sulphide, which may be the sulphinpyrazone metabolite with activity on platelets, was eliminated with a mean half-life of 13.4 h.",Pharmacokinetics of single doses of sulphinpyrazone and its major metabolites in plasma and urine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059415/),h,13.4,122455,DB00812,Phenylbutazone
,7059415,renal clearance,The renal clearance of sulphinpyrazone was approximately 18 ml min-1 and that for the sulphone was similar.,Pharmacokinetics of single doses of sulphinpyrazone and its major metabolites in plasma and urine. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059415/),[ml] / [min],18,122456,DB00812,Phenylbutazone
,7059415,half-lives,Sigma minus plots of the urinary excretion yielded half-lives of 3.5 h for the sulphone and 1 h for p-hydroxy-sulphinpyrazone.,Pharmacokinetics of single doses of sulphinpyrazone and its major metabolites in plasma and urine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059415/),h,3.5,122457,DB00812,Phenylbutazone
,7059415,half-lives,Sigma minus plots of the urinary excretion yielded half-lives of 3.5 h for the sulphone and 1 h for p-hydroxy-sulphinpyrazone.,Pharmacokinetics of single doses of sulphinpyrazone and its major metabolites in plasma and urine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059415/),h,1,122458,DB00812,Phenylbutazone
,10454086,ratio of sodium:chloride excretion,"Administration of frusemide without phenylbutazone led to diuresis, natriuresis, kaliuresis and chloruresis, and altered the ratio of sodium:chloride excretion from 0.4 to 1.0 in the first hour of diuresis.",Attenuation by phenylbutazone of the renal effects and excretion of frusemide in horses. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454086/),,0.4,127126,DB00812,Phenylbutazone
,10454086,ratio of sodium:chloride excretion,"Administration of frusemide without phenylbutazone led to diuresis, natriuresis, kaliuresis and chloruresis, and altered the ratio of sodium:chloride excretion from 0.4 to 1.0 in the first hour of diuresis.",Attenuation by phenylbutazone of the renal effects and excretion of frusemide in horses. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454086/),,1.0,127127,DB00812,Phenylbutazone
,6129344,half-life,Antipyrine half-life was shortened in all patients from a mean value of 12.3 +/- 3.9 h to 7.8 +/- 2.0 h and antipyrine clearance was increased from 39.0 +/- 16.0 ml/min to 57.6 +/- 13.7 ml/min.,Enhanced drug metabolism after sulfinpyrazone treatment in patients aged 50 to 60 years. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129344/),h,12.3,129319,DB00812,Phenylbutazone
,6129344,half-life,Antipyrine half-life was shortened in all patients from a mean value of 12.3 +/- 3.9 h to 7.8 +/- 2.0 h and antipyrine clearance was increased from 39.0 +/- 16.0 ml/min to 57.6 +/- 13.7 ml/min.,Enhanced drug metabolism after sulfinpyrazone treatment in patients aged 50 to 60 years. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129344/),h,7.8,129320,DB00812,Phenylbutazone
,6129344,clearance,Antipyrine half-life was shortened in all patients from a mean value of 12.3 +/- 3.9 h to 7.8 +/- 2.0 h and antipyrine clearance was increased from 39.0 +/- 16.0 ml/min to 57.6 +/- 13.7 ml/min.,Enhanced drug metabolism after sulfinpyrazone treatment in patients aged 50 to 60 years. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129344/),[ml] / [min],39.0,129321,DB00812,Phenylbutazone
,6129344,clearance,Antipyrine half-life was shortened in all patients from a mean value of 12.3 +/- 3.9 h to 7.8 +/- 2.0 h and antipyrine clearance was increased from 39.0 +/- 16.0 ml/min to 57.6 +/- 13.7 ml/min.,Enhanced drug metabolism after sulfinpyrazone treatment in patients aged 50 to 60 years. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129344/),[ml] / [min],57.6,129322,DB00812,Phenylbutazone
,6129344,volume of distribution,"In contrast the volume of distribution of antipyrine was unaffected; the values being 38.0 +/- 8.6 liters and 37.4 +/- 5.7 liters, respectively.",Enhanced drug metabolism after sulfinpyrazone treatment in patients aged 50 to 60 years. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129344/),l,38.0,129323,DB00812,Phenylbutazone
,6129344,volume of distribution,"In contrast the volume of distribution of antipyrine was unaffected; the values being 38.0 +/- 8.6 liters and 37.4 +/- 5.7 liters, respectively.",Enhanced drug metabolism after sulfinpyrazone treatment in patients aged 50 to 60 years. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129344/),l,37.4,129324,DB00812,Phenylbutazone
,6129344,excretion,In all patients the excretion of 6-beta-OH-cortisol in the urine went up from 65.0 +/- 25.7 micrograms/24 h to 346.8 +/- 193.4 micrograms/24 h.,Enhanced drug metabolism after sulfinpyrazone treatment in patients aged 50 to 60 years. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129344/),[μg] / [24·h],65.0,129325,DB00812,Phenylbutazone
,6129344,excretion,In all patients the excretion of 6-beta-OH-cortisol in the urine went up from 65.0 +/- 25.7 micrograms/24 h to 346.8 +/- 193.4 micrograms/24 h.,Enhanced drug metabolism after sulfinpyrazone treatment in patients aged 50 to 60 years. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129344/),[μg] / [24·h],346.8,129326,DB00812,Phenylbutazone
,6129344,GGT,After 21 days of treatment the GGT increased from 17.4 +/- 4.9 units/liter to 32.6 +/- 12.5 units/liter,Enhanced drug metabolism after sulfinpyrazone treatment in patients aged 50 to 60 years. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129344/),[units] / [l],17.4,129327,DB00812,Phenylbutazone
,6129344,GGT,After 21 days of treatment the GGT increased from 17.4 +/- 4.9 units/liter to 32.6 +/- 12.5 units/liter,Enhanced drug metabolism after sulfinpyrazone treatment in patients aged 50 to 60 years. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6129344/),[units] / [l],32.6,129328,DB00812,Phenylbutazone
,6512917,plasma concentrations,"After administering the i.v. schedule for 4 days to Thoroughbred and Standardbred horses at pasture, the mean plasma concentrations of phenylbutazone increased from 0.77 microgram/ml on day 2 to 2.5 micrograms/ml on day 5.",Population distributions of phenylbutazone and oxyphenbutazone after oral and i.v. dosing in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6512917/),,0.77,134846,DB00812,Phenylbutazone
,6512917,plasma concentrations,"After administering the i.v. schedule for 4 days to Thoroughbred and Standardbred horses at pasture, the mean plasma concentrations of phenylbutazone increased from 0.77 microgram/ml on day 2 to 2.5 micrograms/ml on day 5.",Population distributions of phenylbutazone and oxyphenbutazone after oral and i.v. dosing in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6512917/),,2,134847,DB00812,Phenylbutazone
,6512917,plasma concentrations,"After administration of the oral-i.v. schedule to Thoroughbred and Standardbred horses at pasture, the mean plasma concentrations of phenylbutazone were 3.4 micrograms/ml on day 2 and 3.5 micrograms/ml on day 5.",Population distributions of phenylbutazone and oxyphenbutazone after oral and i.v. dosing in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6512917/),[μg] / [ml],3.4,134848,DB00812,Phenylbutazone
,6512917,plasma concentrations,"After administration of the oral-i.v. schedule to Thoroughbred and Standardbred horses at pasture, the mean plasma concentrations of phenylbutazone were 3.4 micrograms/ml on day 2 and 3.5 micrograms/ml on day 5.",Population distributions of phenylbutazone and oxyphenbutazone after oral and i.v. dosing in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6512917/),[μg] / [ml],3.5,134849,DB00812,Phenylbutazone
,6512917,Plasma concentrations,Plasma concentrations on day 5 in these horses averaged 5.3 micrograms/ml.,Population distributions of phenylbutazone and oxyphenbutazone after oral and i.v. dosing in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6512917/),[μg] / [ml],5.3,134850,DB00812,Phenylbutazone
,7674460,steady-state volume of distribution,"For a 150 U/kg CK dose, the steady-state volume of distribution was 0.050 +/- 0.0115 L/kg and the plasma half-life was 112 +/- 18 min.",A non-invasive and quantitative method for the study of tissue injury caused by intramuscular injection of drugs in horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7674460/),[l] / [kg],0.050,135211,DB00812,Phenylbutazone
,7674460,plasma half-life,"For a 150 U/kg CK dose, the steady-state volume of distribution was 0.050 +/- 0.0115 L/kg and the plasma half-life was 112 +/- 18 min.",A non-invasive and quantitative method for the study of tissue injury caused by intramuscular injection of drugs in horses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7674460/),min,112,135212,DB00812,Phenylbutazone
,7674460,half-life of the terminal phase,"After CK i.m. administration, the half-life of the terminal phase was 11.8 +/- 5.3 h indicating a flip-flop process and the mean bioavailability of CK was close to 100%.",A non-invasive and quantitative method for the study of tissue injury caused by intramuscular injection of drugs in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7674460/),h,11.8,135213,DB00812,Phenylbutazone
,7674460,bioavailability,"After CK i.m. administration, the half-life of the terminal phase was 11.8 +/- 5.3 h indicating a flip-flop process and the mean bioavailability of CK was close to 100%.",A non-invasive and quantitative method for the study of tissue injury caused by intramuscular injection of drugs in horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7674460/),%,100,135214,DB00812,Phenylbutazone
,7674460,peak values,"After PBZ i.m. administration, the CK activity was significantly increased with peak values of 508 +/- 109 U/L after the neck administration and 873 +/- 365 U/L after the gluteal administration.",A non-invasive and quantitative method for the study of tissue injury caused by intramuscular injection of drugs in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7674460/),[u] / [l],508,135215,DB00812,Phenylbutazone
,7674460,peak values,"After PBZ i.m. administration, the CK activity was significantly increased with peak values of 508 +/- 109 U/L after the neck administration and 873 +/- 365 U/L after the gluteal administration.",A non-invasive and quantitative method for the study of tissue injury caused by intramuscular injection of drugs in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7674460/),[u] / [l],873,135216,DB00812,Phenylbutazone
,1807089,Minimal detectable concentration,Minimal detectable concentration of serum piroxicam by using HPLC reported in literature was mostly around 50 ng.,[A HPLC method for determining piroxicam in body fluids]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1807089/),ng,50,135527,DB00812,Phenylbutazone
,1807089,detection limit,"A new HPLC method providing a detection limit of 0.75 ng, sensitive enough to quantify low concentrations of serum piroxicam down to 5 ng.",[A HPLC method for determining piroxicam in body fluids]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1807089/),ng,0.75,135528,DB00812,Phenylbutazone
,1807089,flow rate,A mixture of methanol and ammonium acetate 0.1 mol.L-1 (1:0.9 vol.vol-1) was selected as mobile phase with a flow rate of 1 ml.min-1. 0.025% tetramethyl ethylene diamine was added to ammonium acetate solution and adjusted to pH 4.5 with citric acid before mixing.,[A HPLC method for determining piroxicam in body fluids]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1807089/),[ml] / [min],1,135529,DB00812,Phenylbutazone
,1807089,recoveries,"The within-day and day-to-day precisions (CV) of this method were 2.88% and 2.89% respectively, with average recoveries of 96.0-102.4% (10-5,000 ng.ml-1).",[A HPLC method for determining piroxicam in body fluids]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1807089/),%,96.0-102.4,135530,DB00812,Phenylbutazone
,1807089,recoveries,"The within-day and day-to-day precisions (CV) of this method were 2.88% and 2.89% respectively, with average recoveries of 96.0-102.4% (10-5,000 ng.ml-1).",[A HPLC method for determining piroxicam in body fluids]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1807089/),[ng] / [ml],"10-5,000",135531,DB00812,Phenylbutazone
,3370058,plasma elimination half-life,In accordance with the pharmacodynamic characteristics plasma elimination half-life of torasemide was about 1.5 h in the rat and bioavailability was nearly complete.,Chemistry and pharmacological properties of the pyridine-3-sulfonylurea derivative torasemide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370058/),h,1.5,135635,DB00812,Phenylbutazone
,12213119,clearance,"PBZ pharmacokinetics after i.v. dosage was characterized by slow clearance (1.29 mL/kg/h), long-terminal half-life (53.4 h), low distribution volume (0.09 L/kg) and low concentrations in plasma of the metabolite oxyphenbutazone (OPBZ), confirming previously published data for adult cattle.",Pharmacodynamics and pharmacokinetics of phenylbutazone in calves. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213119/),[ml] / [h·kg],1.29,140382,DB00812,Phenylbutazone
,12213119,-terminal half-life,"PBZ pharmacokinetics after i.v. dosage was characterized by slow clearance (1.29 mL/kg/h), long-terminal half-life (53.4 h), low distribution volume (0.09 L/kg) and low concentrations in plasma of the metabolite oxyphenbutazone (OPBZ), confirming previously published data for adult cattle.",Pharmacodynamics and pharmacokinetics of phenylbutazone in calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213119/),h,53.4,140383,DB00812,Phenylbutazone
,12213119,distribution volume,"PBZ pharmacokinetics after i.v. dosage was characterized by slow clearance (1.29 mL/kg/h), long-terminal half-life (53.4 h), low distribution volume (0.09 L/kg) and low concentrations in plasma of the metabolite oxyphenbutazone (OPBZ), confirming previously published data for adult cattle.",Pharmacodynamics and pharmacokinetics of phenylbutazone in calves. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213119/),[l] / [kg],0.09,140384,DB00812,Phenylbutazone
,12213119,bioavailability (F),After oral dosage bioavailability (F) was 66%.,Pharmacodynamics and pharmacokinetics of phenylbutazone in calves. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213119/),%,66,140385,DB00812,Phenylbutazone
,12213119,area under curve,"Passage into exudate was slow and limited, and penetration into transudate was even slower and more limited; area under curve values for plasma, exudate and transudate after i.v. dosage were 3604, 1117 and 766 microg h/mL and corresponding values after oral dosage were 2435, 647 and 486 microg h/mL.",Pharmacodynamics and pharmacokinetics of phenylbutazone in calves. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213119/),[h·μg] / [ml],3604,140386,DB00812,Phenylbutazone
,12213119,area under curve,"Passage into exudate was slow and limited, and penetration into transudate was even slower and more limited; area under curve values for plasma, exudate and transudate after i.v. dosage were 3604, 1117 and 766 microg h/mL and corresponding values after oral dosage were 2435, 647 and 486 microg h/mL.",Pharmacodynamics and pharmacokinetics of phenylbutazone in calves. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213119/),[h·μg] / [ml],1117,140387,DB00812,Phenylbutazone
,12213119,area under curve,"Passage into exudate was slow and limited, and penetration into transudate was even slower and more limited; area under curve values for plasma, exudate and transudate after i.v. dosage were 3604, 1117 and 766 microg h/mL and corresponding values after oral dosage were 2435, 647 and 486 microg h/mL.",Pharmacodynamics and pharmacokinetics of phenylbutazone in calves. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213119/),[h·μg] / [ml],766,140388,DB00812,Phenylbutazone
,12213119,area under curve,"Passage into exudate was slow and limited, and penetration into transudate was even slower and more limited; area under curve values for plasma, exudate and transudate after i.v. dosage were 3604, 1117 and 766 microg h/mL and corresponding values after oral dosage were 2435, 647 and 486 microg h/mL.",Pharmacodynamics and pharmacokinetics of phenylbutazone in calves. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213119/),[h·μg] / [ml],2435,140389,DB00812,Phenylbutazone
,12213119,area under curve,"Passage into exudate was slow and limited, and penetration into transudate was even slower and more limited; area under curve values for plasma, exudate and transudate after i.v. dosage were 3604, 1117 and 766 microg h/mL and corresponding values after oral dosage were 2435, 647 and 486 microg h/mL.",Pharmacodynamics and pharmacokinetics of phenylbutazone in calves. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213119/),[h·μg] / [ml],647,140390,DB00812,Phenylbutazone
,12213119,area under curve,"Passage into exudate was slow and limited, and penetration into transudate was even slower and more limited; area under curve values for plasma, exudate and transudate after i.v. dosage were 3604, 1117 and 766 microg h/mL and corresponding values after oral dosage were 2435, 647 and 486 microg h/mL.",Pharmacodynamics and pharmacokinetics of phenylbutazone in calves. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12213119/),[h·μg] / [ml],486,140391,DB00812,Phenylbutazone
,9731952,plasma clearance (CLp),Median plasma clearance (CLp) of furosemide in anaesthetized horses with BUL was 1.4 mL/min/kg.,The pharmacokinetics of furosemide in anaesthetized horses after bilateral ureteral ligation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9731952/),[ml] / [kg·min],1.4,146342,DB00812,Phenylbutazone
,9731952,Apparent steady state volume of distribution (Vd(ss)),Apparent steady state volume of distribution (Vd(ss)) ranged from 169 to 880 mL/kg and the elimination half life (t1/2) ranged from 83 min to 209 h.,The pharmacokinetics of furosemide in anaesthetized horses after bilateral ureteral ligation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9731952/),[ml] / [kg],169 to 880,146343,DB00812,Phenylbutazone
,9731952,elimination half life (t1/2),Apparent steady state volume of distribution (Vd(ss)) ranged from 169 to 880 mL/kg and the elimination half life (t1/2) ranged from 83 min to 209 h.,The pharmacokinetics of furosemide in anaesthetized horses after bilateral ureteral ligation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9731952/),min,83,146344,DB00812,Phenylbutazone
,9731952,elimination half life (t1/2),Apparent steady state volume of distribution (Vd(ss)) ranged from 169 to 880 mL/kg and the elimination half life (t1/2) ranged from 83 min to 209 h.,The pharmacokinetics of furosemide in anaesthetized horses after bilateral ureteral ligation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9731952/),h,209,146345,DB00812,Phenylbutazone
<,8024649,plasma clearances,"However, based on literature data for 18 non-steroidal anti-inflammatory drugs (NSAIDs) with low plasma clearances (< 60 ml/min), we have shown that most of these low-extraction compounds are non-restrictively eliminated, i.e. their hepatic extraction ratio exceeds their unbound fraction in plasma.",Non-steroidal anti-inflammatory drugs: restrictive or non-restrictive hepatic clearance? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8024649/),[ml] / [min],60,146392,DB00812,Phenylbutazone
,15320597,peak serum concentration,"Use of the TTS resulted in variable serum concentrations of fentanyl, with a peak serum concentration of 2.2+/-1.1 ng/mL (mean+/-SD) and a time to peak serum concentration of 26+/-13 hours.",Transdermal fentanyl combined with nonsteroidal anti-inflammatory drugs for analgesia in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15320597/),[ng] / [ml],2.2,149699,DB00812,Phenylbutazone
,15320597,time to peak serum concentration,"Use of the TTS resulted in variable serum concentrations of fentanyl, with a peak serum concentration of 2.2+/-1.1 ng/mL (mean+/-SD) and a time to peak serum concentration of 26+/-13 hours.",Transdermal fentanyl combined with nonsteroidal anti-inflammatory drugs for analgesia in horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15320597/),h,26,149700,DB00812,Phenylbutazone
,15320597,time to reach serum fentanyl concentrations,"After transdermal fentanyl administration, mean time to reach serum fentanyl concentrations consistent with analgesia in other species (1 ng/mL) was 14 hours.",Transdermal fentanyl combined with nonsteroidal anti-inflammatory drugs for analgesia in horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15320597/),h,1,149701,DB00812,Phenylbutazone
,15320597,time to reach serum fentanyl concentrations,"After transdermal fentanyl administration, mean time to reach serum fentanyl concentrations consistent with analgesia in other species (1 ng/mL) was 14 hours.",Transdermal fentanyl combined with nonsteroidal anti-inflammatory drugs for analgesia in horses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15320597/),h,14,149702,DB00812,Phenylbutazone
,6519123,ka,The blood concentration/time course was found to fit a two compartment open model with first order absorption (ka = 10.1 h-1) where elimination (kel = 0.304 h-1) occurs only from compartment 1.,Pharmacokinetics of [4-14C] mofebutazone after oral administration in man. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6519123/),1/[h],10.1,155398,DB00812,Phenylbutazone
,6519123,kel,The blood concentration/time course was found to fit a two compartment open model with first order absorption (ka = 10.1 h-1) where elimination (kel = 0.304 h-1) occurs only from compartment 1.,Pharmacokinetics of [4-14C] mofebutazone after oral administration in man. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6519123/),1/[h],0.304,155399,DB00812,Phenylbutazone
,6519123,renal clearance,The renal clearance of mofebutazone in man was found to be 3.38 l/h.,Pharmacokinetics of [4-14C] mofebutazone after oral administration in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6519123/),[l] / [h],3.38,155400,DB00812,Phenylbutazone
,22082440,Peak PBZ plasma concentration,Peak PBZ plasma concentration was 73.7 ± 6.0 and 77.9 ± 5.5 µg/ml.,Phenylbutazone and flunixin meglumine used singly or in combination in experimental lameness in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22082440/),[μg] / [ml],73.7,158209,DB00812,Phenylbutazone
,22082440,Peak PBZ plasma concentration,Peak PBZ plasma concentration was 73.7 ± 6.0 and 77.9 ± 5.5 µg/ml.,Phenylbutazone and flunixin meglumine used singly or in combination in experimental lameness in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22082440/),[μg] / [ml],77.9,158210,DB00812,Phenylbutazone
,22082440,Peak FM concentration,Peak FM concentration was 12.0 ± 0.8 and 13.7 ± 1.0 µg/ml.,Phenylbutazone and flunixin meglumine used singly or in combination in experimental lameness in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22082440/),[μg] / [ml],12.0,158211,DB00812,Phenylbutazone
,22082440,Peak FM concentration,Peak FM concentration was 12.0 ± 0.8 and 13.7 ± 1.0 µg/ml.,Phenylbutazone and flunixin meglumine used singly or in combination in experimental lameness in horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22082440/),[μg] / [ml],13.7,158212,DB00812,Phenylbutazone
,8989496,total body clearance,"Mean total body clearance of phenylbutazone in horses was fivefold less than that in donkeys (29.3 and 170.3 ml/kg/h, respectively).",Comparative pharmacokinetics of phenylbutazone and its metabolite oxyphenbutazone in clinically normal horses and donkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8989496/),[ml] / [h·kg],29.3,162244,DB00812,Phenylbutazone
,8989496,total body clearance,"Mean total body clearance of phenylbutazone in horses was fivefold less than that in donkeys (29.3 and 170.3 ml/kg/h, respectively).",Comparative pharmacokinetics of phenylbutazone and its metabolite oxyphenbutazone in clinically normal horses and donkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8989496/),[ml] / [h·kg],170.3,162245,DB00812,Phenylbutazone
,8989496,area under the curve,"Mean values for area under the curve and mean residence time in horses (118.3 micrograms/h/ml and 3.6 hours, respectively) were significantly greater than values in donkeys (28.3 micrograms/h/ml and 1.7 hours, respectively).",Comparative pharmacokinetics of phenylbutazone and its metabolite oxyphenbutazone in clinically normal horses and donkeys. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8989496/),[μg] / [h·ml],118.3,162246,DB00812,Phenylbutazone
,8989496,area under the curve,"Mean values for area under the curve and mean residence time in horses (118.3 micrograms/h/ml and 3.6 hours, respectively) were significantly greater than values in donkeys (28.3 micrograms/h/ml and 1.7 hours, respectively).",Comparative pharmacokinetics of phenylbutazone and its metabolite oxyphenbutazone in clinically normal horses and donkeys. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8989496/),[μg] / [h·ml],28.3,162247,DB00812,Phenylbutazone
,8989496,mean residence time,"Mean values for area under the curve and mean residence time in horses (118.3 micrograms/h/ml and 3.6 hours, respectively) were significantly greater than values in donkeys (28.3 micrograms/h/ml and 1.7 hours, respectively).",Comparative pharmacokinetics of phenylbutazone and its metabolite oxyphenbutazone in clinically normal horses and donkeys. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8989496/),h,3.6,162248,DB00812,Phenylbutazone
,8989496,mean residence time,"Mean values for area under the curve and mean residence time in horses (118.3 micrograms/h/ml and 3.6 hours, respectively) were significantly greater than values in donkeys (28.3 micrograms/h/ml and 1.7 hours, respectively).",Comparative pharmacokinetics of phenylbutazone and its metabolite oxyphenbutazone in clinically normal horses and donkeys. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8989496/),h,1.7,162249,DB00812,Phenylbutazone
,8989496,time to peak concentration,"For oxyphenbutazone, mean time to peak concentration in donkeys was significantly less than that in horses (1.6 and 6.4 hours, respectively).",Comparative pharmacokinetics of phenylbutazone and its metabolite oxyphenbutazone in clinically normal horses and donkeys. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8989496/),h,1.6,162250,DB00812,Phenylbutazone
,8989496,time to peak concentration,"For oxyphenbutazone, mean time to peak concentration in donkeys was significantly less than that in horses (1.6 and 6.4 hours, respectively).",Comparative pharmacokinetics of phenylbutazone and its metabolite oxyphenbutazone in clinically normal horses and donkeys. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8989496/),h,6.4,162251,DB00812,Phenylbutazone
,1820333,half-time,"The half-time of the toxin depends on both the dose and the animal species, varying from 0.7 h in fish to 840 h in monkeys.",Pharmacokinetics of ochratoxin A in animals. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820333/),h,0.7,166163,DB00812,Phenylbutazone
,1820333,half-time,"The half-time of the toxin depends on both the dose and the animal species, varying from 0.7 h in fish to 840 h in monkeys.",Pharmacokinetics of ochratoxin A in animals. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820333/),h,840,166164,DB00812,Phenylbutazone
,1920602,maximal concentration,The excretion rate peaked after 2-3 h while the maximal concentration ranged from 18.5 to 80.6 micrograms/ml.,Disposition of human drug preparations in the horse. I. Rectally administered indomethacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1920602/),[μg] / [ml],18.5 to 80.6,169660,DB00812,Phenylbutazone
,8230399,beta half-life,The disposition of the metabolite PBZ (i.v.) could be described by a 2 compartment model with a beta half-life varying from 7.40 to 8.35 h.,The disposition of suxibuzone in the horse. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8230399/),h,7.40 to 8.35,169857,DB00812,Phenylbutazone
,8230399,Peak plasma PBZ concentrations,Peak plasma PBZ concentrations (8.8 +/- 3.0 micrograms/ml) occurred 6 h after oral dosing and the terminal exponential constant was 0.11 +/- 0.01 h-1.,The disposition of suxibuzone in the horse. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8230399/),[μg] / [ml],8.8,169858,DB00812,Phenylbutazone
,8230399,terminal exponential constant,Peak plasma PBZ concentrations (8.8 +/- 3.0 micrograms/ml) occurred 6 h after oral dosing and the terminal exponential constant was 0.11 +/- 0.01 h-1.,The disposition of suxibuzone in the horse. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8230399/),1/[h],0.11,169859,DB00812,Phenylbutazone
,3816927,total recovery,The total recovery in urine of all compounds varied from 30-56% of the dose.,Renal clearance of sulphinpyrazone in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3816927/),%,30-56,173003,DB00812,Phenylbutazone
,3816927,mean residence time,"In two subjects the mean residence time of sulphinpyrazone was twice as long as in the other subjects (10.4 h compared with 4.6 h), but the area under the plasma concentration-time curve was comparable to that in the others (mean: 3.0 mg X ml-1 X min), indicating that drug absorption was quantitatively similar but delayed.",Renal clearance of sulphinpyrazone in man. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3816927/),h,10.4,173004,DB00812,Phenylbutazone
,3816927,mean residence time,"In two subjects the mean residence time of sulphinpyrazone was twice as long as in the other subjects (10.4 h compared with 4.6 h), but the area under the plasma concentration-time curve was comparable to that in the others (mean: 3.0 mg X ml-1 X min), indicating that drug absorption was quantitatively similar but delayed.",Renal clearance of sulphinpyrazone in man. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3816927/),h,4.6,173005,DB00812,Phenylbutazone
,3816927,area under the plasma concentration-time curve,"In two subjects the mean residence time of sulphinpyrazone was twice as long as in the other subjects (10.4 h compared with 4.6 h), but the area under the plasma concentration-time curve was comparable to that in the others (mean: 3.0 mg X ml-1 X min), indicating that drug absorption was quantitatively similar but delayed.",Renal clearance of sulphinpyrazone in man. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3816927/),[mg·min] / [ml],3.0,173006,DB00812,Phenylbutazone
,3816927,renal clearance,The renal clearance of sulphinpyrazone varied from 14-40 ml X min-1 (mean: 28 ml X min-1).,Renal clearance of sulphinpyrazone in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3816927/),[ml] / [min],28,173007,DB00812,Phenylbutazone
,3816927,renal clearance,"The same holds for the sulphone metabolite, which has a mean renal clearance of 24 ml X min-1, and even more for the p-hydroxysulphinpyrazone metabolite, which has a renal clearance of 118 ml X min-1.",Renal clearance of sulphinpyrazone in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3816927/),[ml] / [min],24,173008,DB00812,Phenylbutazone
,3816927,renal clearance,"The same holds for the sulphone metabolite, which has a mean renal clearance of 24 ml X min-1, and even more for the p-hydroxysulphinpyrazone metabolite, which has a renal clearance of 118 ml X min-1.",Renal clearance of sulphinpyrazone in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3816927/),[ml] / [min],118,173009,DB00812,Phenylbutazone
,9185972,elimination half-life,Mean +/- SEM elimination half-life was 13.44 +/- 0.44 hours.,Pharmacokinetics of phenylbutazone in camels. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9185972/),h,13.44,173539,DB00812,Phenylbutazone
,9185972,Total body clearance,Total body clearance was 12.63 +/- 1.64 mg/kg/h.,Pharmacokinetics of phenylbutazone in camels. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9185972/),[mg] / [h·kg],12.63,173540,DB00812,Phenylbutazone
,9185972,elimination half-life,The elimination half-life of oxyphenbutazone was 23.9 +/- 2.09 hours.,Pharmacokinetics of phenylbutazone in camels. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9185972/),h,23.9,173541,DB00812,Phenylbutazone
,7707492,EC50,"Plasma drug concentrations and pharmacodynamic data were analysed according to an integrated PK/PD model; for the stride length, the PBZ EC50, i.e. the plasma concentration for which half the maximum effect could be obtained, was 3.6 +/- 2.2 micrograms/ml and the maximum potential effect was 10.7 +/- 9.4% above the control value.",Plasma concentrations and therapeutic efficacy of phenylbutazone and flunixin meglumine in the horse: pharmacokinetic/pharmacodynamic modelling. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7707492/),[μg] / [ml],3.6,173975,DB00812,Phenylbutazone
,7707492,half the maximum effect,"Plasma drug concentrations and pharmacodynamic data were analysed according to an integrated PK/PD model; for the stride length, the PBZ EC50, i.e. the plasma concentration for which half the maximum effect could be obtained, was 3.6 +/- 2.2 micrograms/ml and the maximum potential effect was 10.7 +/- 9.4% above the control value.",Plasma concentrations and therapeutic efficacy of phenylbutazone and flunixin meglumine in the horse: pharmacokinetic/pharmacodynamic modelling. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7707492/),[μg] / [ml],3.6,173976,DB00812,Phenylbutazone
,8310707,elimination half-life (t1/2),"2. For RA patients, the mean elimination half-life (t1/2) of feprazone after a single oral dose was 21 +/- 5 h (SD), the mean apparent clearance (Cl) was 0.012 +/- 0.009 l/h per kg, and the mean apparent volume of distribution (Vd) was 0.33 +/- 0.17 l/kg.",Pharmacokinetics of single oral doses of feprazone in patients with rheumatoid arthritis or with impaired renal clearance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8310707/),h,21,175609,DB00812,Phenylbutazone
,8310707,apparent clearance (Cl),"2. For RA patients, the mean elimination half-life (t1/2) of feprazone after a single oral dose was 21 +/- 5 h (SD), the mean apparent clearance (Cl) was 0.012 +/- 0.009 l/h per kg, and the mean apparent volume of distribution (Vd) was 0.33 +/- 0.17 l/kg.",Pharmacokinetics of single oral doses of feprazone in patients with rheumatoid arthritis or with impaired renal clearance. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8310707/),[l] / [h·kg],0.012,175610,DB00812,Phenylbutazone
,8310707,apparent volume of distribution (Vd),"2. For RA patients, the mean elimination half-life (t1/2) of feprazone after a single oral dose was 21 +/- 5 h (SD), the mean apparent clearance (Cl) was 0.012 +/- 0.009 l/h per kg, and the mean apparent volume of distribution (Vd) was 0.33 +/- 0.17 l/kg.",Pharmacokinetics of single oral doses of feprazone in patients with rheumatoid arthritis or with impaired renal clearance. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8310707/),[l] / [kg],0.33,175611,DB00812,Phenylbutazone
,8126767,bioavailability,The mean i.m. bioavailability of phenylbutazone was calculated to be 91.7 +/- 10.1%.,The intramuscular bioavailability of a phenylbutazone preparation in the horse. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126767/),%,91.7,177268,DB00812,Phenylbutazone
,3568689,beta,"A 72-hour blood sampling schedule failed to demonstrate a third exponential phase; the plasma disposition following intravenous injection being described by a two compartment open model, with the following elimination phase parameters: beta = 0.13h-1, t1/2 beta = 5.46h, Vdarea = 0.141 1/kg and C1B = 17.9 ml/kg/h.","Metabolism, excretion, pharmacokinetics and tissue residues of phenylbutazone in the horse. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3568689/),1/[h],0.13,177493,DB00812,Phenylbutazone
,3568689,t1/2 beta,"A 72-hour blood sampling schedule failed to demonstrate a third exponential phase; the plasma disposition following intravenous injection being described by a two compartment open model, with the following elimination phase parameters: beta = 0.13h-1, t1/2 beta = 5.46h, Vdarea = 0.141 1/kg and C1B = 17.9 ml/kg/h.","Metabolism, excretion, pharmacokinetics and tissue residues of phenylbutazone in the horse. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3568689/),h,5.46,177494,DB00812,Phenylbutazone
,3568689,Vdarea,"A 72-hour blood sampling schedule failed to demonstrate a third exponential phase; the plasma disposition following intravenous injection being described by a two compartment open model, with the following elimination phase parameters: beta = 0.13h-1, t1/2 beta = 5.46h, Vdarea = 0.141 1/kg and C1B = 17.9 ml/kg/h.","Metabolism, excretion, pharmacokinetics and tissue residues of phenylbutazone in the horse. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3568689/),[1] / [kg],0.141,177495,DB00812,Phenylbutazone
,3568689,C1B,"A 72-hour blood sampling schedule failed to demonstrate a third exponential phase; the plasma disposition following intravenous injection being described by a two compartment open model, with the following elimination phase parameters: beta = 0.13h-1, t1/2 beta = 5.46h, Vdarea = 0.141 1/kg and C1B = 17.9 ml/kg/h.","Metabolism, excretion, pharmacokinetics and tissue residues of phenylbutazone in the horse. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3568689/),[ml] / [h·kg],17.9,177496,DB00812,Phenylbutazone
,3568689,percentages,"The percentages of the administered dose recovered from urine were 30.7, 39.0 and 40.3 after 24, 48 and 72 h from the time of injection.","Metabolism, excretion, pharmacokinetics and tissue residues of phenylbutazone in the horse. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3568689/),,30,177497,DB00812,Phenylbutazone
,3568689,percentages,"The percentages of the administered dose recovered from urine were 30.7, 39.0 and 40.3 after 24, 48 and 72 h from the time of injection.","Metabolism, excretion, pharmacokinetics and tissue residues of phenylbutazone in the horse. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3568689/),,39.0,177498,DB00812,Phenylbutazone
,3568689,percentages,"The percentages of the administered dose recovered from urine were 30.7, 39.0 and 40.3 after 24, 48 and 72 h from the time of injection.","Metabolism, excretion, pharmacokinetics and tissue residues of phenylbutazone in the horse. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3568689/),,40.3,177499,DB00812,Phenylbutazone
,3701913,time to peak concentration,"When access to hay was permitted before and after dosing, the mean time to peak concentration was 13.2 +/- 1.2 h and double peaks in the plasma concentration-time curve were common.",Absorption and pharmacokinetics of phenylbutazone in Welsh Mountain ponies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3701913/),h,13.2,180845,DB00812,Phenylbutazone
,3701913,times to peak concentration,"In this circumstance, mean times to peak concentration were much shorter (3.8 +/- 1.3 h after morning dosing and 5.3 +/- 1.5 h followed afternoon dosing).",Absorption and pharmacokinetics of phenylbutazone in Welsh Mountain ponies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3701913/),h,3.8,180846,DB00812,Phenylbutazone
,3701913,times to peak concentration,"In this circumstance, mean times to peak concentration were much shorter (3.8 +/- 1.3 h after morning dosing and 5.3 +/- 1.5 h followed afternoon dosing).",Absorption and pharmacokinetics of phenylbutazone in Welsh Mountain ponies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3701913/),h,5.3,180847,DB00812,Phenylbutazone
,3701913,Bioavailability,Bioavailability was estimated to be approximately 69% in fed and 78% in unfed ponies.,Absorption and pharmacokinetics of phenylbutazone in Welsh Mountain ponies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3701913/),%,69,180848,DB00812,Phenylbutazone
,3701913,Bioavailability,Bioavailability was estimated to be approximately 69% in fed and 78% in unfed ponies.,Absorption and pharmacokinetics of phenylbutazone in Welsh Mountain ponies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3701913/),%,78,180849,DB00812,Phenylbutazone
,3701913,bioavailability,Estimates of bioavailability gave similar values for morning (72%) and afternoon (71%) dosing.,Absorption and pharmacokinetics of phenylbutazone in Welsh Mountain ponies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3701913/),%,72,180850,DB00812,Phenylbutazone
,3701913,bioavailability,Estimates of bioavailability gave similar values for morning (72%) and afternoon (71%) dosing.,Absorption and pharmacokinetics of phenylbutazone in Welsh Mountain ponies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3701913/),%,71,180851,DB00812,Phenylbutazone
,6705446,ClAP,"In contrast, sulfinpyrazone pretreatment increased ClAP by 23% (from 5.70 +/- 0.21 to 7.00 +/- 0.39 ml/min/kg) and ClAP was 46% greater in the epileptic subjects who received anticonvulsant drugs than in the control group (8.32 +/- 0.45 and 5.70 +/- 0.21 ml/ml/kg).",Determinants of acetaminophen metabolism: effect of inducers and inhibitors of drug metabolism on acetaminophen's metabolic pathways. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705446/),[ml] / [kg·min],5.70,180973,DB00812,Phenylbutazone
,6705446,ClAP,"In contrast, sulfinpyrazone pretreatment increased ClAP by 23% (from 5.70 +/- 0.21 to 7.00 +/- 0.39 ml/min/kg) and ClAP was 46% greater in the epileptic subjects who received anticonvulsant drugs than in the control group (8.32 +/- 0.45 and 5.70 +/- 0.21 ml/ml/kg).",Determinants of acetaminophen metabolism: effect of inducers and inhibitors of drug metabolism on acetaminophen's metabolic pathways. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705446/),[ml] / [kg·min],7.00,180974,DB00812,Phenylbutazone
,6705446,ClAP,"In contrast, sulfinpyrazone pretreatment increased ClAP by 23% (from 5.70 +/- 0.21 to 7.00 +/- 0.39 ml/min/kg) and ClAP was 46% greater in the epileptic subjects who received anticonvulsant drugs than in the control group (8.32 +/- 0.45 and 5.70 +/- 0.21 ml/ml/kg).",Determinants of acetaminophen metabolism: effect of inducers and inhibitors of drug metabolism on acetaminophen's metabolic pathways. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705446/),[ml] / [kg·ml],8.32,180975,DB00812,Phenylbutazone
,6705446,ClAP,"In contrast, sulfinpyrazone pretreatment increased ClAP by 23% (from 5.70 +/- 0.21 to 7.00 +/- 0.39 ml/min/kg) and ClAP was 46% greater in the epileptic subjects who received anticonvulsant drugs than in the control group (8.32 +/- 0.45 and 5.70 +/- 0.21 ml/ml/kg).",Determinants of acetaminophen metabolism: effect of inducers and inhibitors of drug metabolism on acetaminophen's metabolic pathways. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6705446/),[ml] / [kg·ml],5.70,180976,DB00812,Phenylbutazone
,9885966,volume of distribution at steady state (Vss),"In regards to whole plasma data, the mean volume of distribution at steady state (Vss), was 147 mL/kg body weight, with a mean (+/-SEM) terminal elimination half-life (t1/2) of 40+/-6 h.",Pharmacokinetics of phenylbutazone in plasma and milk of lactating dairy cows. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9885966/),[ml] / [kg],147,181525,DB00812,Phenylbutazone
,9885966,terminal elimination half-life (t1/2),"In regards to whole plasma data, the mean volume of distribution at steady state (Vss), was 147 mL/kg body weight, with a mean (+/-SEM) terminal elimination half-life (t1/2) of 40+/-6 h.",Pharmacokinetics of phenylbutazone in plasma and milk of lactating dairy cows. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9885966/),h,40,181526,DB00812,Phenylbutazone
,9885966,clearance (Cl),The mean clearance (Cl) was 3 mL/h/kg body weight.,Pharmacokinetics of phenylbutazone in plasma and milk of lactating dairy cows. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9885966/),[ml] / [h·kg],3,181527,DB00812,Phenylbutazone
,9885966,Vss,The Vss as determined from the protein-free plasma fraction was 50021 mL/kg body weight.,Pharmacokinetics of phenylbutazone in plasma and milk of lactating dairy cows. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9885966/),[ml] / [kg],50021,181528,DB00812,Phenylbutazone
,9885966,t1/2,The mean t1/2 of free phenylbutazone was 39+/-5 h.,Pharmacokinetics of phenylbutazone in plasma and milk of lactating dairy cows. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9885966/),h,39,181529,DB00812,Phenylbutazone
,9885966,t1/2,"Mean t1/2 as determined from milk, applying a urinary excretion rate model, was 47+/-4 h.",Pharmacokinetics of phenylbutazone in plasma and milk of lactating dairy cows. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9885966/),h,47,181530,DB00812,Phenylbutazone
,9885966,Milk clearance,"Milk clearance of phenylbutazone was 0.009 mL/h/kg body weight, or about 0.34% of total body clearance.",Pharmacokinetics of phenylbutazone in plasma and milk of lactating dairy cows. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9885966/),[ml] / [h·kg],0.009,181531,DB00812,Phenylbutazone
,2928755,plasma elimination half-life,The plasma elimination half-life of carprofen ranged from 44.5 to 64.6 h after repeated daily injections.,"Carprofen in veterinary medicine. I. Plasma disposition, milk excretion and tolerance in milk-producing cows. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2928755/),h,44.5 to 64.6,186982,DB00812,Phenylbutazone
,2928755,volume of distribution,The volume of distribution and the clearance values calculated after a single intravenous injection amounted to 0.09 l/kg and 9.0 ml/min.,"Carprofen in veterinary medicine. I. Plasma disposition, milk excretion and tolerance in milk-producing cows. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2928755/),[l] / [kg],0.09,186983,DB00812,Phenylbutazone
,2928755,clearance,The volume of distribution and the clearance values calculated after a single intravenous injection amounted to 0.09 l/kg and 9.0 ml/min.,"Carprofen in veterinary medicine. I. Plasma disposition, milk excretion and tolerance in milk-producing cows. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2928755/),[ml] / [min],9.0,186984,DB00812,Phenylbutazone
,11341383,mean residence time,"Values for mean residence time ranged from 0.5 to 3.0 hours (median, 1.1 hour), whereas total body clearance ranged from 4.2 to 7.5 ml/kg/min (mean, 5.8 ml/kg/min).",Pharmacokinetics of phenylbutazone and its metabolite oxyphenbutazone in miniature donkeys. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11341383/),h,1.1,194316,DB00812,Phenylbutazone
,11341383,total body clearance,"Values for mean residence time ranged from 0.5 to 3.0 hours (median, 1.1 hour), whereas total body clearance ranged from 4.2 to 7.5 ml/kg/min (mean, 5.8 ml/kg/min).",Pharmacokinetics of phenylbutazone and its metabolite oxyphenbutazone in miniature donkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11341383/),[ml] / [kg·min],5.8,194317,DB00812,Phenylbutazone
,11341383,time to peak concentration,"Oxyphenbutazone appeared rapidly in the serum; time to peak concentration ranged from 13 to 41 minutes (mean, 26.4 minutes), and peak concentration in serum ranged from 2.8 to 4.0 mg/ml (mean, 3.5 microg/ml).",Pharmacokinetics of phenylbutazone and its metabolite oxyphenbutazone in miniature donkeys. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11341383/),min,26.4,194318,DB00812,Phenylbutazone
,11341383,peak concentration,"Oxyphenbutazone appeared rapidly in the serum; time to peak concentration ranged from 13 to 41 minutes (mean, 26.4 minutes), and peak concentration in serum ranged from 2.8 to 4.0 mg/ml (mean, 3.5 microg/ml).",Pharmacokinetics of phenylbutazone and its metabolite oxyphenbutazone in miniature donkeys. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11341383/),[μg] / [ml],3.5,194319,DB00812,Phenylbutazone
,2920698,half-life of elimination,The half-life of elimination of phenylbutazone alone was about 4 h.,"Interactions between chloramphenicol, acepromazine, phenylbutazone, rifampin and thiamylal in the horse. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2920698/),h,4,198483,DB00812,Phenylbutazone
,10499236,area under the concentration-time curve (AUC0-->LOQ),"Mean plasma concentration of PBZ peaked at 5 h (34.5 +/- 6.7 micrograms/mL) and at 7 h (38.8 +/- 8.4 micrograms/mL), and mean area under the concentration-time curve (AUC0-->LOQ) was 608.0 +/- 162.2 micrograms.h/mL and 656.6 +/- 149.7 micrograms.h/mL after granulate and paste administration, respectively.",Pharmacokinetics and bioequivalence of two suxibuzone oral dosage forms in horses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499236/),[h·μg] / [ml],608.0,199016,DB00812,Phenylbutazone
,10499236,area under the concentration-time curve (AUC0-->LOQ),"Mean plasma concentration of PBZ peaked at 5 h (34.5 +/- 6.7 micrograms/mL) and at 7 h (38.8 +/- 8.4 micrograms/mL), and mean area under the concentration-time curve (AUC0-->LOQ) was 608.0 +/- 162.2 micrograms.h/mL and 656.6 +/- 149.7 micrograms.h/mL after granulate and paste administration, respectively.",Pharmacokinetics and bioequivalence of two suxibuzone oral dosage forms in horses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499236/),[h·μg] / [ml],656.6,199017,DB00812,Phenylbutazone
,10499236,AUCs0-->LOQ,The AUCs0-->LOQ for OPBZ were also similar (141.8 +/- 48.3 micrograms.h/mL granulate vs. 171.4 +/- 45.0 micrograms.h/mL paste).,Pharmacokinetics and bioequivalence of two suxibuzone oral dosage forms in horses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499236/),[h·μg] / [ml],141.8,199018,DB00812,Phenylbutazone
,10499236,AUCs0-->LOQ,The AUCs0-->LOQ for OPBZ were also similar (141.8 +/- 48.3 micrograms.h/mL granulate vs. 171.4 +/- 45.0 micrograms.h/mL paste).,Pharmacokinetics and bioequivalence of two suxibuzone oral dosage forms in horses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10499236/),[h·μg] / [ml],171.4,199019,DB00812,Phenylbutazone
,8766906,half-life time,"After i.v. injection, the half-life time of phenylbutazone has been determined to be 6.6-6.7 h.",[The concentration changes of different phenylbutazone formulations in horse plasma]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8766906/),h,6.6-6.7,209426,DB00812,Phenylbutazone
,8766906,absorption rat constant,The absorption rat constant of the paste suspension was found to be higher than that of the powder (1.797-2.304 h-1 vs. 0.656-1.197 h-1).,[The concentration changes of different phenylbutazone formulations in horse plasma]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8766906/),1/[h],1.797-2.304,209427,DB00812,Phenylbutazone
,8766906,absorption rat constant,The absorption rat constant of the paste suspension was found to be higher than that of the powder (1.797-2.304 h-1 vs. 0.656-1.197 h-1).,[The concentration changes of different phenylbutazone formulations in horse plasma]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8766906/),1/[h],0.656-1.197,209428,DB00812,Phenylbutazone
,8766906,bioavailability,The bioavailability of the studied powder and paste formulation was calculated to be 55.1-96.7%.,[The concentration changes of different phenylbutazone formulations in horse plasma]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8766906/),%,55.1-96.7,209429,DB00812,Phenylbutazone
,8766906,minimal therapeutic level,The minimal therapeutic level of 5 micrograms/ml was attained 0.2-0.8 hours after administration of the drug and lasted 8.2-22 hours depending on the dose applied.,[The concentration changes of different phenylbutazone formulations in horse plasma]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8766906/),[μg] / [ml],5,209430,DB00812,Phenylbutazone
,9731955,elimination half-life (t1/2beta),Plasma kinetics showed that FM had an elimination half-life (t1/2beta) of 2.48 +/- 0.12 h and an area under the concentration - time curve (AUC) of 30.61 +/- 3.41 Lg/mL x h.,"Pharmacokinetic studies of flunixin meglumine and phenylbutazone in plasma, exudate and transudate in sheep. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9731955/),h,2.48,214839,DB00812,Phenylbutazone
,9731955,area under the concentration - time curve (AUC),Plasma kinetics showed that FM had an elimination half-life (t1/2beta) of 2.48 +/- 0.12 h and an area under the concentration - time curve (AUC) of 30.61 +/- 3.41 Lg/mL x h.,"Pharmacokinetic studies of flunixin meglumine and phenylbutazone in plasma, exudate and transudate in sheep. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9731955/),[lg] / [h·ml],30.61,214840,DB00812,Phenylbutazone
,9731955,t1/2beta,"Elimination of PBZ from plasma was slow (t1/2beta = 17.92 +/- 1.74 h, AUC = 968.04 +/- microg/mL x h).","Pharmacokinetic studies of flunixin meglumine and phenylbutazone in plasma, exudate and transudate in sheep. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9731955/),h,17.92,214841,DB00812,Phenylbutazone
,9731955,AUC,"Elimination of PBZ from plasma was slow (t1/2beta = 17.92 +/- 1.74 h, AUC = 968.04 +/- microg/mL x h).","Pharmacokinetic studies of flunixin meglumine and phenylbutazone in plasma, exudate and transudate in sheep. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9731955/),[μg] / [h·ml],968.04,214842,DB00812,Phenylbutazone
,9731955,maximal drug concentration (Cmax),"Both FM and PBZ distributed well into exudate and transudate although penetration was slow, indicated by maximal drug concentration (Cmax) for FM of 1.82 +/- 0.22 microg/mL at 5.50 +/- 0.73 h (exudate) and 1.58 +/- 0.30 microg/mL at 8.00 h (transudate), and Cmax for PBZ of 22.32 +/- 1.29 microg/mL at 9.50 +/- 0.73 h (exudate) and 22.07 +/- 1.57 microg/mL at 11.50 +/- 1.92 h (transudate), and a high mean tissue-cage fluids:plasma AUClast ratio obtained in the FM and PBZ groups (80-98%).","Pharmacokinetic studies of flunixin meglumine and phenylbutazone in plasma, exudate and transudate in sheep. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9731955/),[μg] / [ml],1.82,214843,DB00812,Phenylbutazone
,9731955,maximal drug concentration (Cmax),"Both FM and PBZ distributed well into exudate and transudate although penetration was slow, indicated by maximal drug concentration (Cmax) for FM of 1.82 +/- 0.22 microg/mL at 5.50 +/- 0.73 h (exudate) and 1.58 +/- 0.30 microg/mL at 8.00 h (transudate), and Cmax for PBZ of 22.32 +/- 1.29 microg/mL at 9.50 +/- 0.73 h (exudate) and 22.07 +/- 1.57 microg/mL at 11.50 +/- 1.92 h (transudate), and a high mean tissue-cage fluids:plasma AUClast ratio obtained in the FM and PBZ groups (80-98%).","Pharmacokinetic studies of flunixin meglumine and phenylbutazone in plasma, exudate and transudate in sheep. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9731955/),[μg] / [ml],1.58,214844,DB00812,Phenylbutazone
,9731955,Cmax,"Both FM and PBZ distributed well into exudate and transudate although penetration was slow, indicated by maximal drug concentration (Cmax) for FM of 1.82 +/- 0.22 microg/mL at 5.50 +/- 0.73 h (exudate) and 1.58 +/- 0.30 microg/mL at 8.00 h (transudate), and Cmax for PBZ of 22.32 +/- 1.29 microg/mL at 9.50 +/- 0.73 h (exudate) and 22.07 +/- 1.57 microg/mL at 11.50 +/- 1.92 h (transudate), and a high mean tissue-cage fluids:plasma AUClast ratio obtained in the FM and PBZ groups (80-98%).","Pharmacokinetic studies of flunixin meglumine and phenylbutazone in plasma, exudate and transudate in sheep. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9731955/),[μg] / [ml],22.32,214845,DB00812,Phenylbutazone
,9731955,Cmax,"Both FM and PBZ distributed well into exudate and transudate although penetration was slow, indicated by maximal drug concentration (Cmax) for FM of 1.82 +/- 0.22 microg/mL at 5.50 +/- 0.73 h (exudate) and 1.58 +/- 0.30 microg/mL at 8.00 h (transudate), and Cmax for PBZ of 22.32 +/- 1.29 microg/mL at 9.50 +/- 0.73 h (exudate) and 22.07 +/- 1.57 microg/mL at 11.50 +/- 1.92 h (transudate), and a high mean tissue-cage fluids:plasma AUClast ratio obtained in the FM and PBZ groups (80-98%).","Pharmacokinetic studies of flunixin meglumine and phenylbutazone in plasma, exudate and transudate in sheep. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9731955/),[μg] / [ml],22.07,214846,DB00812,Phenylbutazone
,9731955,fluids:plasma AUClast ratio,"Both FM and PBZ distributed well into exudate and transudate although penetration was slow, indicated by maximal drug concentration (Cmax) for FM of 1.82 +/- 0.22 microg/mL at 5.50 +/- 0.73 h (exudate) and 1.58 +/- 0.30 microg/mL at 8.00 h (transudate), and Cmax for PBZ of 22.32 +/- 1.29 microg/mL at 9.50 +/- 0.73 h (exudate) and 22.07 +/- 1.57 microg/mL at 11.50 +/- 1.92 h (transudate), and a high mean tissue-cage fluids:plasma AUClast ratio obtained in the FM and PBZ groups (80-98%).","Pharmacokinetic studies of flunixin meglumine and phenylbutazone in plasma, exudate and transudate in sheep. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9731955/),%,80-98,214847,DB00812,Phenylbutazone
,7112870,AUC (0 to 24 hours),"Administration of phenylbutazone (5 mg/kg) following an overnight fast resulted in no difference among the three groups of animals with respect to AUC (0 to 24 hours), mean (+/- sd) values of which were 132 +/- 68, 107 +/- 48 and 98 +/- 6, respectively.",Factors affecting absorption of non-steroidal anti-inflammatory agents in the horse. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7112870/),,132,229638,DB00812,Phenylbutazone
,7112870,AUC (0 to 24 hours),"Administration of phenylbutazone (5 mg/kg) following an overnight fast resulted in no difference among the three groups of animals with respect to AUC (0 to 24 hours), mean (+/- sd) values of which were 132 +/- 68, 107 +/- 48 and 98 +/- 6, respectively.",Factors affecting absorption of non-steroidal anti-inflammatory agents in the horse. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7112870/),,107,229639,DB00812,Phenylbutazone
,7112870,AUC (0 to 24 hours),"Administration of phenylbutazone (5 mg/kg) following an overnight fast resulted in no difference among the three groups of animals with respect to AUC (0 to 24 hours), mean (+/- sd) values of which were 132 +/- 68, 107 +/- 48 and 98 +/- 6, respectively.",Factors affecting absorption of non-steroidal anti-inflammatory agents in the horse. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7112870/),,98,229640,DB00812,Phenylbutazone
,8291771,Elimination half-life,"Elimination half-life was 207 and 168 hours, and clearance was 0.708 and 0.828 ml/kg/h in healthy and endotoxemic calves, respectively.",Pharmacokinetics and effects of repeated administration of phenylbutazone in neonatal calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8291771/),h,207,233544,DB00812,Phenylbutazone
,8291771,Elimination half-life,"Elimination half-life was 207 and 168 hours, and clearance was 0.708 and 0.828 ml/kg/h in healthy and endotoxemic calves, respectively.",Pharmacokinetics and effects of repeated administration of phenylbutazone in neonatal calves. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8291771/),h,168,233545,DB00812,Phenylbutazone
,8291771,clearance,"Elimination half-life was 207 and 168 hours, and clearance was 0.708 and 0.828 ml/kg/h in healthy and endotoxemic calves, respectively.",Pharmacokinetics and effects of repeated administration of phenylbutazone in neonatal calves. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8291771/),[ml] / [h·kg],0.708,233546,DB00812,Phenylbutazone
,8291771,clearance,"Elimination half-life was 207 and 168 hours, and clearance was 0.708 and 0.828 ml/kg/h in healthy and endotoxemic calves, respectively.",Pharmacokinetics and effects of repeated administration of phenylbutazone in neonatal calves. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8291771/),[ml] / [h·kg],0.828,233547,DB00812,Phenylbutazone
,3176523,half-life,"2. 14C-Feprazone had a half-life of 30-33 h, similar to that after single dosage of unlabelled feprazone (22-33 h).",The disposition of feprazone and its hydroxylated metabolite in human volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3176523/),h,30-33,236220,DB00812,Phenylbutazone
,3176523,half-life,"2. 14C-Feprazone had a half-life of 30-33 h, similar to that after single dosage of unlabelled feprazone (22-33 h).",The disposition of feprazone and its hydroxylated metabolite in human volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3176523/),h,22-33,236221,DB00812,Phenylbutazone
,3176523,time of peak plasma concentration,"The time of peak plasma concentration of feprazone was 4-5 h after dosage, and of 4'-hydroxyfeprazone was approx.",The disposition of feprazone and its hydroxylated metabolite in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3176523/),h,4-5,236222,DB00812,Phenylbutazone
,3176523,plasma elimination half-life,"5:1. 4. When 4'-hydroxyfeprazone was administered as a single oral dose to a human volunteer the plasma elimination half-life of the metabolite was 18 h, but after administration of feprazone the half-life of 4'-hydroxyfeprazone was 45 +/- 29 h (10 subjects), indicating the slow hydroxylation of feprazone and the slow excretion of 4'-hydroxyfeprazone.",The disposition of feprazone and its hydroxylated metabolite in human volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3176523/),h,18,236223,DB00812,Phenylbutazone
,3176523,half-life,"5:1. 4. When 4'-hydroxyfeprazone was administered as a single oral dose to a human volunteer the plasma elimination half-life of the metabolite was 18 h, but after administration of feprazone the half-life of 4'-hydroxyfeprazone was 45 +/- 29 h (10 subjects), indicating the slow hydroxylation of feprazone and the slow excretion of 4'-hydroxyfeprazone.",The disposition of feprazone and its hydroxylated metabolite in human volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3176523/),h,45,236224,DB00812,Phenylbutazone
,3176523,clearance,The clearance of feprazone was 5.2 and of 4'-hydroxyfeprazone was 5.5 ml/kg/h.,The disposition of feprazone and its hydroxylated metabolite in human volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3176523/),[ml] / [h·kg],5.2,236225,DB00812,Phenylbutazone
,3176523,clearance,The clearance of feprazone was 5.2 and of 4'-hydroxyfeprazone was 5.5 ml/kg/h.,The disposition of feprazone and its hydroxylated metabolite in human volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3176523/),[ml] / [h·kg],5.5,236226,DB00812,Phenylbutazone
,9049950,volume of distribution,"After intravenous (i.v.) administration, disposition was characterised by a two-compartment open model, with a low volume of distribution (0.174 l.kg-1), and distribution and elimination half-lives of 0.43 and 12.51 h, respectively.",Phenylbutazone pharmacokinetics and bioavailability in the dromedary camel (Camelus dromedarius). ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049950/),[l] / [kg],0.174,237163,DB00812,Phenylbutazone
,9049950,distribution,"After intravenous (i.v.) administration, disposition was characterised by a two-compartment open model, with a low volume of distribution (0.174 l.kg-1), and distribution and elimination half-lives of 0.43 and 12.51 h, respectively.",Phenylbutazone pharmacokinetics and bioavailability in the dromedary camel (Camelus dromedarius). ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049950/),h,0.43,237164,DB00812,Phenylbutazone
,9049950,elimination half-lives,"After intravenous (i.v.) administration, disposition was characterised by a two-compartment open model, with a low volume of distribution (0.174 l.kg-1), and distribution and elimination half-lives of 0.43 and 12.51 h, respectively.",Phenylbutazone pharmacokinetics and bioavailability in the dromedary camel (Camelus dromedarius). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049950/),h,12.51,237165,DB00812,Phenylbutazone
,9049950,absorption half-time,"After intramuscular (i.m.) dosing absorption was relatively rapid with absorption half-time and time of maximal concentration values of 1.14 and 3.95 h, respectively.",Phenylbutazone pharmacokinetics and bioavailability in the dromedary camel (Camelus dromedarius). ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049950/),h,1.14,237166,DB00812,Phenylbutazone
,9049950,time of maximal concentration,"After intramuscular (i.m.) dosing absorption was relatively rapid with absorption half-time and time of maximal concentration values of 1.14 and 3.95 h, respectively.",Phenylbutazone pharmacokinetics and bioavailability in the dromedary camel (Camelus dromedarius). ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049950/),h,3.95,237167,DB00812,Phenylbutazone
,9049950,bioavailability,"Plateau concentrations of phenylbutazone in plasma were obtained between 2 and 12 h and mean bioavailability was 97%, although this was subject to wide inter-animal differences.",Phenylbutazone pharmacokinetics and bioavailability in the dromedary camel (Camelus dromedarius). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9049950/),%,97,237168,DB00812,Phenylbutazone
,33480571,serum concentration peaks,Dosages of 1.5 mg/kg flunixin resulted in mean serum concentration peaks of 7.2 ± 1.5 µg/ml in Asian elephants (n = 7) and 4.4 ± 0.7 µg/ml in African elephants (n = 6).,PHARMACOKINETICS OF ORALLY ADMINISTERED FLUNIXIN MEGLUMINE IN AFRICAN (LOXODONTA AFRICANA) AND ASIAN (ELEPHAS MAXIMUS) ELEPHANTS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33480571/),[μg] / [ml],7.2,237539,DB00812,Phenylbutazone
,33480571,serum concentration peaks,Dosages of 1.5 mg/kg flunixin resulted in mean serum concentration peaks of 7.2 ± 1.5 µg/ml in Asian elephants (n = 7) and 4.4 ± 0.7 µg/ml in African elephants (n = 6).,PHARMACOKINETICS OF ORALLY ADMINISTERED FLUNIXIN MEGLUMINE IN AFRICAN (LOXODONTA AFRICANA) AND ASIAN (ELEPHAS MAXIMUS) ELEPHANTS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33480571/),[μg] / [ml],4.4,237540,DB00812,Phenylbutazone
,33480571,peak serum concentrations,"However, multiple-dose trials using 1.1 mg/kg flunixin resulted in peak serum concentrations that were again less in Asian than African elephants (2.7 µg/ml versus 4.4 µg/ml, respectively).",PHARMACOKINETICS OF ORALLY ADMINISTERED FLUNIXIN MEGLUMINE IN AFRICAN (LOXODONTA AFRICANA) AND ASIAN (ELEPHAS MAXIMUS) ELEPHANTS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33480571/),[μg] / [ml],2.7,237541,DB00812,Phenylbutazone
,33480571,peak serum concentrations,"However, multiple-dose trials using 1.1 mg/kg flunixin resulted in peak serum concentrations that were again less in Asian than African elephants (2.7 µg/ml versus 4.4 µg/ml, respectively).",PHARMACOKINETICS OF ORALLY ADMINISTERED FLUNIXIN MEGLUMINE IN AFRICAN (LOXODONTA AFRICANA) AND ASIAN (ELEPHAS MAXIMUS) ELEPHANTS. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33480571/),[μg] / [ml],4.4,237542,DB00812,Phenylbutazone
,6241720,relative BA,"Compared to the phenylbutazone i.v. injection, the phenylbutazone dragées proved a complete substance uptake into the systemic circulation, whereas a relative BA of 65% has been determined for Perclusone capsules.",[Comparative studies on the bioavailability of various drug forms of phenylbutazone and clofezone (Perclusone)]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6241720/),%,65,238311,DB00812,Phenylbutazone
,8971677,total body clearance (CLB,"However, small but significant increases (P < 0.05) in total body clearance (CLB; 29.2 +/- 3.9 vs. 43.8 +/- 8.1 mL/ h.kg) and the volume of distribution, calculated by area (Vd(area); 0.18+/- 0.05 vs. 0.25 +/- 0.03 L/kg) or at steady-state (Vd(SS); 0.17 +/- 0.04 vs. 0.25 +/- 0.03 L/ kg), were obtained in horses after adjuvant injection, compared to controls, when PBZ was administered at 4.4 mg/kg which corresponded to relatively higher tissues concentrations and lower plasma concentrations (calculated) at the time of maximum peripheral PBZ concentration.",The effect of inflammation on the disposition of phenylbutazone in thoroughbred horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971677/),[ml] / [h·kg],29.2,239040,DB00812,Phenylbutazone
,8971677,total body clearance (CLB,"However, small but significant increases (P < 0.05) in total body clearance (CLB; 29.2 +/- 3.9 vs. 43.8 +/- 8.1 mL/ h.kg) and the volume of distribution, calculated by area (Vd(area); 0.18+/- 0.05 vs. 0.25 +/- 0.03 L/kg) or at steady-state (Vd(SS); 0.17 +/- 0.04 vs. 0.25 +/- 0.03 L/ kg), were obtained in horses after adjuvant injection, compared to controls, when PBZ was administered at 4.4 mg/kg which corresponded to relatively higher tissues concentrations and lower plasma concentrations (calculated) at the time of maximum peripheral PBZ concentration.",The effect of inflammation on the disposition of phenylbutazone in thoroughbred horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971677/),[ml] / [h·kg],43.8,239041,DB00812,Phenylbutazone
,8971677,area (Vd(area),"However, small but significant increases (P < 0.05) in total body clearance (CLB; 29.2 +/- 3.9 vs. 43.8 +/- 8.1 mL/ h.kg) and the volume of distribution, calculated by area (Vd(area); 0.18+/- 0.05 vs. 0.25 +/- 0.03 L/kg) or at steady-state (Vd(SS); 0.17 +/- 0.04 vs. 0.25 +/- 0.03 L/ kg), were obtained in horses after adjuvant injection, compared to controls, when PBZ was administered at 4.4 mg/kg which corresponded to relatively higher tissues concentrations and lower plasma concentrations (calculated) at the time of maximum peripheral PBZ concentration.",The effect of inflammation on the disposition of phenylbutazone in thoroughbred horses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971677/),[l] / [kg],0.18,239042,DB00812,Phenylbutazone
,8971677,area (Vd(area),"However, small but significant increases (P < 0.05) in total body clearance (CLB; 29.2 +/- 3.9 vs. 43.8 +/- 8.1 mL/ h.kg) and the volume of distribution, calculated by area (Vd(area); 0.18+/- 0.05 vs. 0.25 +/- 0.03 L/kg) or at steady-state (Vd(SS); 0.17 +/- 0.04 vs. 0.25 +/- 0.03 L/ kg), were obtained in horses after adjuvant injection, compared to controls, when PBZ was administered at 4.4 mg/kg which corresponded to relatively higher tissues concentrations and lower plasma concentrations (calculated) at the time of maximum peripheral PBZ concentration.",The effect of inflammation on the disposition of phenylbutazone in thoroughbred horses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971677/),[l] / [kg],0.25,239043,DB00812,Phenylbutazone
,8971677,steady-state (Vd(SS),"However, small but significant increases (P < 0.05) in total body clearance (CLB; 29.2 +/- 3.9 vs. 43.8 +/- 8.1 mL/ h.kg) and the volume of distribution, calculated by area (Vd(area); 0.18+/- 0.05 vs. 0.25 +/- 0.03 L/kg) or at steady-state (Vd(SS); 0.17 +/- 0.04 vs. 0.25 +/- 0.03 L/ kg), were obtained in horses after adjuvant injection, compared to controls, when PBZ was administered at 4.4 mg/kg which corresponded to relatively higher tissues concentrations and lower plasma concentrations (calculated) at the time of maximum peripheral PBZ concentration.",The effect of inflammation on the disposition of phenylbutazone in thoroughbred horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971677/),[l] / [kg],0.17,239044,DB00812,Phenylbutazone
,8971677,steady-state (Vd(SS),"However, small but significant increases (P < 0.05) in total body clearance (CLB; 29.2 +/- 3.9 vs. 43.8 +/- 8.1 mL/ h.kg) and the volume of distribution, calculated by area (Vd(area); 0.18+/- 0.05 vs. 0.25 +/- 0.03 L/kg) or at steady-state (Vd(SS); 0.17 +/- 0.04 vs. 0.25 +/- 0.03 L/ kg), were obtained in horses after adjuvant injection, compared to controls, when PBZ was administered at 4.4 mg/kg which corresponded to relatively higher tissues concentrations and lower plasma concentrations (calculated) at the time of maximum peripheral PBZ concentration.",The effect of inflammation on the disposition of phenylbutazone in thoroughbred horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971677/),[l] / [kg],0.25,239045,DB00812,Phenylbutazone
,582952,maximum plasma levels,"A single dose of 300 mg pyrazinobutazone produces maximum plasma levels of 35.2 +/- 1.1 micrograms/ml at 5.5 h after administration (+/- SEM, 70 kg bodyweight, N = 39).",The pharmacokinetic profile of pyrazinobutazone in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/582952/),[μg] / [ml],35.2,243414,DB00812,Phenylbutazone
,3433258,concentrations of,The average concentrations of dipyridamole at steady-state were 26 +/- 15 and 79 +/- 69 ng/ml after 2.5 and 10 mg/kg/day.,Effective antiplatelet drug concentrations in experimental arterial thromboembolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3433258/),[ng] / [ml],26,247723,DB00812,Phenylbutazone
,3433258,concentrations of,The average concentrations of dipyridamole at steady-state were 26 +/- 15 and 79 +/- 69 ng/ml after 2.5 and 10 mg/kg/day.,Effective antiplatelet drug concentrations in experimental arterial thromboembolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3433258/),[ng] / [ml],79,247724,DB00812,Phenylbutazone
,3433258,at steady-state,The average concentrations of dipyridamole at steady-state were 26 +/- 15 and 79 +/- 69 ng/ml after 2.5 and 10 mg/kg/day.,Effective antiplatelet drug concentrations in experimental arterial thromboembolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3433258/),[ng] / [ml],26,247725,DB00812,Phenylbutazone
,3433258,at steady-state,The average concentrations of dipyridamole at steady-state were 26 +/- 15 and 79 +/- 69 ng/ml after 2.5 and 10 mg/kg/day.,Effective antiplatelet drug concentrations in experimental arterial thromboembolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3433258/),[ng] / [ml],79,247726,DB00812,Phenylbutazone
,3433258,steady-state concentrations,"The average steady-state concentrations of acetylsalicylic and salicylic acids were 0.67 +/- 0.80 and 3.76 +/- 2.60 micrograms/ml, respectively, after 20 mg/kg/day.",Effective antiplatelet drug concentrations in experimental arterial thromboembolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3433258/),[μg] / [ml],0.67,247727,DB00812,Phenylbutazone
,3433258,steady-state concentrations,"The average steady-state concentrations of acetylsalicylic and salicylic acids were 0.67 +/- 0.80 and 3.76 +/- 2.60 micrograms/ml, respectively, after 20 mg/kg/day.",Effective antiplatelet drug concentrations in experimental arterial thromboembolism. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3433258/),[μg] / [ml],3.76,247728,DB00812,Phenylbutazone
,8345564,elimination half-life (t 1/2 beta),The elimination half-life (t 1/2 beta) of PBZ decreased from 120 h in the 1-day-old to 16 h in the adult goats.,"The effect of age on phenylbutazone pharmacokinetics, metabolism and plasma protein binding in goats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8345564/),h,120,250355,DB00812,Phenylbutazone
,8345564,elimination half-life (t 1/2 beta),The elimination half-life (t 1/2 beta) of PBZ decreased from 120 h in the 1-day-old to 16 h in the adult goats.,"The effect of age on phenylbutazone pharmacokinetics, metabolism and plasma protein binding in goats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8345564/),h,16,250356,DB00812,Phenylbutazone
,8345564,total body clearance (Cl B),"Although the volume of distribution (Vd) did not change significantly during maturation, the total body clearance (Cl B) increased from 2 ml.h-1.kg-1 in 1-day-old to 13 ml.h-1.kg-1 in the adult goats; the increase was 2-fold in the first 10 days of life.","The effect of age on phenylbutazone pharmacokinetics, metabolism and plasma protein binding in goats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8345564/),[ml] / [h·kg],2,250357,DB00812,Phenylbutazone
,8345564,total body clearance (Cl B),"Although the volume of distribution (Vd) did not change significantly during maturation, the total body clearance (Cl B) increased from 2 ml.h-1.kg-1 in 1-day-old to 13 ml.h-1.kg-1 in the adult goats; the increase was 2-fold in the first 10 days of life.","The effect of age on phenylbutazone pharmacokinetics, metabolism and plasma protein binding in goats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8345564/),[ml] / [h·kg],13,250358,DB00812,Phenylbutazone
,2316912,biologic half-life,The harmonic mean +/- pseudo-SD of the biologic half-life of PBZ was 61.8 +/- 12.8 hours.,Pharmacokinetics of phenylbutazone in mature Holstein bulls: steady-state kinetics after multiple oral dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316912/),h,61.8,251376,DB00812,Phenylbutazone
,2316912,total body clearance,"The arithmetic mean +/- SEM of the total body clearance and apparent volume of distribution were 0.0021 +/- 0.0001 L/h/kg and 0.201 +/- 0.009 L/kg, respectively.",Pharmacokinetics of phenylbutazone in mature Holstein bulls: steady-state kinetics after multiple oral dosing. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316912/),[l] / [h·kg],0.0021,251377,DB00812,Phenylbutazone
,2316912,apparent volume of distribution,"The arithmetic mean +/- SEM of the total body clearance and apparent volume of distribution were 0.0021 +/- 0.0001 L/h/kg and 0.201 +/- 0.009 L/kg, respectively.",Pharmacokinetics of phenylbutazone in mature Holstein bulls: steady-state kinetics after multiple oral dosing. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316912/),[l] / [kg],0.201,251378,DB00812,Phenylbutazone
,2316912,minimal plasma concentration,The predicted mean minimal plasma concentration of PBZ with this dosage regimen was 75.06 +/- 4.05 micrograms/ml.,Pharmacokinetics of phenylbutazone in mature Holstein bulls: steady-state kinetics after multiple oral dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316912/),[μg] / [ml],75.06,251379,DB00812,Phenylbutazone
,2316912,observed minimal plasma concentration,"The mean observed minimal plasma concentration of PBZ in the 16 bulls was 76.10 +/- 2.04 micrograms/ml, whereas the mean predicted minimal plasma concentration was 74.69 +/- 3.10 micrograms/ml.",Pharmacokinetics of phenylbutazone in mature Holstein bulls: steady-state kinetics after multiple oral dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316912/),[μg] / [ml],76.10,251380,DB00812,Phenylbutazone
,2316912,minimal plasma concentration,"The mean observed minimal plasma concentration of PBZ in the 16 bulls was 76.10 +/- 2.04 micrograms/ml, whereas the mean predicted minimal plasma concentration was 74.69 +/- 3.10 micrograms/ml.",Pharmacokinetics of phenylbutazone in mature Holstein bulls: steady-state kinetics after multiple oral dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316912/),[μg] / [ml],74.69,251381,DB00812,Phenylbutazone
,2316912,minimal steady-state concentrations,"Dosages of 4 to 6 mg of PBZ/kg, q 24 h, or 10 to 14 mg of PBZ/kg, q 48 h, provided therapeutic plasma concentrations of PBZ with minimal steady-state concentrations between 50 and 70 micrograms/ml.",Pharmacokinetics of phenylbutazone in mature Holstein bulls: steady-state kinetics after multiple oral dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2316912/),[μg] / [ml],50 and 70,251382,DB00812,Phenylbutazone
,234284,protein binding,"The degree of protein binding (pbz 98%, ox-pbz 97%), the apparent specific volume of distribution (pbz 0.18 1/kg, ox-pbz 0.28 1/kg) and the renal clearance were found to be similar to results obtained in man and rat.",Pharmacokinetics of phenylbutazone and oxyphenabutazone in the pig. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/234284/),%,98,251475,DB00812,Phenylbutazone
,234284,protein binding,"The degree of protein binding (pbz 98%, ox-pbz 97%), the apparent specific volume of distribution (pbz 0.18 1/kg, ox-pbz 0.28 1/kg) and the renal clearance were found to be similar to results obtained in man and rat.",Pharmacokinetics of phenylbutazone and oxyphenabutazone in the pig. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/234284/),%,97,251476,DB00812,Phenylbutazone
,234284,apparent specific volume of distribution,"The degree of protein binding (pbz 98%, ox-pbz 97%), the apparent specific volume of distribution (pbz 0.18 1/kg, ox-pbz 0.28 1/kg) and the renal clearance were found to be similar to results obtained in man and rat.",Pharmacokinetics of phenylbutazone and oxyphenabutazone in the pig. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/234284/),[1] / [kg],0.18,251477,DB00812,Phenylbutazone
,234284,apparent specific volume of distribution,"The degree of protein binding (pbz 98%, ox-pbz 97%), the apparent specific volume of distribution (pbz 0.18 1/kg, ox-pbz 0.28 1/kg) and the renal clearance were found to be similar to results obtained in man and rat.",Pharmacokinetics of phenylbutazone and oxyphenabutazone in the pig. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/234284/),[1] / [kg],0.28,251478,DB00812,Phenylbutazone
,234284,renal clearance,"Ox-pbz had a higher renal clearance (0.13 ml/min/kg) than pbz (0.003 ml/min/kg) but still the renal excretion constituted only a small fraction of the total elimination (pbz 0.5%, ox-pbz 5%).",Pharmacokinetics of phenylbutazone and oxyphenabutazone in the pig. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/234284/),[ml] / [kg·min],0.13,251479,DB00812,Phenylbutazone
,234284,renal clearance,"Ox-pbz had a higher renal clearance (0.13 ml/min/kg) than pbz (0.003 ml/min/kg) but still the renal excretion constituted only a small fraction of the total elimination (pbz 0.5%, ox-pbz 5%).",Pharmacokinetics of phenylbutazone and oxyphenabutazone in the pig. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/234284/),[ml] / [kg·min],0.003,251480,DB00812,Phenylbutazone
,8611958,flow-rate,The mobile phase was 4.5% 2-propanol in 0.1 M phosphate buffer (pH 6.2) with a flow-rate of 0.9 ml/min.,High-performance liquid chromatographic determination of thiopentone enantiomers in sheep plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8611958/),[ml] / [min],0.9,252593,DB00812,Phenylbutazone
,8611958,k',"This gave k' values of 1.92, 2.92, 5.71, 9.30 and 11.98 for R(+)-pentobarbitone, S(-)-pentobarbitone, R(+)-thiopentone, S(-)-thiopentone, and phenylbutazone, respectively.",High-performance liquid chromatographic determination of thiopentone enantiomers in sheep plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8611958/),,1.92,252594,DB00812,Phenylbutazone
,8611958,k',"This gave k' values of 1.92, 2.92, 5.71, 9.30 and 11.98 for R(+)-pentobarbitone, S(-)-pentobarbitone, R(+)-thiopentone, S(-)-thiopentone, and phenylbutazone, respectively.",High-performance liquid chromatographic determination of thiopentone enantiomers in sheep plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8611958/),,2.92,252595,DB00812,Phenylbutazone
,8611958,k',"This gave k' values of 1.92, 2.92, 5.71, 9.30 and 11.98 for R(+)-pentobarbitone, S(-)-pentobarbitone, R(+)-thiopentone, S(-)-thiopentone, and phenylbutazone, respectively.",High-performance liquid chromatographic determination of thiopentone enantiomers in sheep plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8611958/),,5.71,252596,DB00812,Phenylbutazone
,8611958,k',"This gave k' values of 1.92, 2.92, 5.71, 9.30 and 11.98 for R(+)-pentobarbitone, S(-)-pentobarbitone, R(+)-thiopentone, S(-)-thiopentone, and phenylbutazone, respectively.",High-performance liquid chromatographic determination of thiopentone enantiomers in sheep plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8611958/),,9.30,252597,DB00812,Phenylbutazone
,8611958,k',"This gave k' values of 1.92, 2.92, 5.71, 9.30 and 11.98 for R(+)-pentobarbitone, S(-)-pentobarbitone, R(+)-thiopentone, S(-)-thiopentone, and phenylbutazone, respectively.",High-performance liquid chromatographic determination of thiopentone enantiomers in sheep plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8611958/),,11.98,252598,DB00812,Phenylbutazone
,7924124,kd,"The five parameters associated with the complete pharmacodynamic model were kd (0.054 +/- 0.014 hr-1), the degradation rate constant of PCA; Cu50,S (0.0026 +/- 0.0015 mg.L-1) and Cu50,R (3.45 +/- 4.20 mg.L-1), the unbound concentrations of (S)- and (R)-warfarin required to produce a 50% reduction in PCA synthesis if administered individually; gamma (0.90 +/- 0.23), the slope parameter in the sigmoid Emax model; and td (8.2 +/- 0.3 hours), the observed delay in the onset of warfarin anticoagulant response.",Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924124/),1/[h],0.054,254945,DB00812,Phenylbutazone
,7924124,"Cu50,S","The five parameters associated with the complete pharmacodynamic model were kd (0.054 +/- 0.014 hr-1), the degradation rate constant of PCA; Cu50,S (0.0026 +/- 0.0015 mg.L-1) and Cu50,R (3.45 +/- 4.20 mg.L-1), the unbound concentrations of (S)- and (R)-warfarin required to produce a 50% reduction in PCA synthesis if administered individually; gamma (0.90 +/- 0.23), the slope parameter in the sigmoid Emax model; and td (8.2 +/- 0.3 hours), the observed delay in the onset of warfarin anticoagulant response.",Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924124/),[mg] / [l],0.0026,254946,DB00812,Phenylbutazone
,7924124,"Cu50,R","The five parameters associated with the complete pharmacodynamic model were kd (0.054 +/- 0.014 hr-1), the degradation rate constant of PCA; Cu50,S (0.0026 +/- 0.0015 mg.L-1) and Cu50,R (3.45 +/- 4.20 mg.L-1), the unbound concentrations of (S)- and (R)-warfarin required to produce a 50% reduction in PCA synthesis if administered individually; gamma (0.90 +/- 0.23), the slope parameter in the sigmoid Emax model; and td (8.2 +/- 0.3 hours), the observed delay in the onset of warfarin anticoagulant response.",Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924124/),[mg] / [l],3.45,254947,DB00812,Phenylbutazone
,7924124,gamma,"The five parameters associated with the complete pharmacodynamic model were kd (0.054 +/- 0.014 hr-1), the degradation rate constant of PCA; Cu50,S (0.0026 +/- 0.0015 mg.L-1) and Cu50,R (3.45 +/- 4.20 mg.L-1), the unbound concentrations of (S)- and (R)-warfarin required to produce a 50% reduction in PCA synthesis if administered individually; gamma (0.90 +/- 0.23), the slope parameter in the sigmoid Emax model; and td (8.2 +/- 0.3 hours), the observed delay in the onset of warfarin anticoagulant response.",Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924124/),,0.90,254948,DB00812,Phenylbutazone
,7924124,td,"The five parameters associated with the complete pharmacodynamic model were kd (0.054 +/- 0.014 hr-1), the degradation rate constant of PCA; Cu50,S (0.0026 +/- 0.0015 mg.L-1) and Cu50,R (3.45 +/- 4.20 mg.L-1), the unbound concentrations of (S)- and (R)-warfarin required to produce a 50% reduction in PCA synthesis if administered individually; gamma (0.90 +/- 0.23), the slope parameter in the sigmoid Emax model; and td (8.2 +/- 0.3 hours), the observed delay in the onset of warfarin anticoagulant response.",Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924124/),h,8.2,254949,DB00812,Phenylbutazone
,26512724,maximum plasma concentration (Cmax),"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),[ng] / [ml],1051.8,256545,DB00812,Phenylbutazone
,26512724,maximum plasma concentration (Cmax),"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),[ng] / [ml],335.9,256546,DB00812,Phenylbutazone
,26512724,maximum plasma concentration (Cmax),"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),[ng] / [ml],11150,256547,DB00812,Phenylbutazone
,26512724,maximum plasma concentration (Cmax),"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),h,4,256548,DB00812,Phenylbutazone
,26512724,Tmax,"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),h,5.3,256549,DB00812,Phenylbutazone
,26512724,half-life of elimination,"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),h,13.3,256550,DB00812,Phenylbutazone
,26512724,half-life of elimination,"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),h,1.8,256551,DB00812,Phenylbutazone
,26512724,half-life of elimination,"CRP, FXN and PBZ were characterised by a maximum plasma concentration (Cmax) of 1051.8 ± 620.7 ng/ml, 335.9 ± 36.3 ng/ml and 11150 ± 2474.9 ng/ml at 4 ± 4.3, 0.45 ± 0.02 and 5.3 ± 5.2 hours (Tmax) respectively and a half-life of elimination of 13.3 ±5, 1.8±1 and 18.7 ±11.4 hours respectively.","The Safety and Pharmacokinetics of Carprofen, Flunixin and Phenylbutazone in the Cape Vulture (Gyps coprotheres) following Oral Exposure. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26512724/),h,18.7,256552,DB00812,Phenylbutazone
,6661352,elimination half-life,"The mean elimination half-life of S-warfarin was increased from 25 to 46 h during phenylbutazone administration, whilst that of the R-isomer was decreased from 37 to 25 h.",Phenylbutazone-warfarin interaction in man: further stereochemical and metabolic considerations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6661352/),h,25 to 46,269888,DB00812,Phenylbutazone
,6661352,elimination half-life,"The mean elimination half-life of S-warfarin was increased from 25 to 46 h during phenylbutazone administration, whilst that of the R-isomer was decreased from 37 to 25 h.",Phenylbutazone-warfarin interaction in man: further stereochemical and metabolic considerations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6661352/),h,37 to 25,269889,DB00812,Phenylbutazone
,8964239,elimination half life,Naproxen concentrations (elimination half life of about 72 h in dogs) achieved equilibrium between tissue fluid and plasma concentration.,[The tissue cage in dogs--a pharmacologic model for the representation of plasma and tissue kinetics]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8964239/),h,72,273622,DB00812,Phenylbutazone
